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The explanatory study examines the possible value of Machine Learning in the B2B sales 
process in pharmaceutical companies. Sales representatives accounting for a wide range of 
activities, suffering from time consuming and repetitive tasks. This study investigates the 
potential of Machine Learning applications for B2B sales in order to facilitate sales 
representative’s daily tasks and enhance the entire sales process. The results have been obtained 
through qualitative research based on 8 interviews with AI-experts, pharma consultants and 
sales representatives as well as secondary data in form of academic articles and reports. The 
findings reveal that, compared to other departments, ML-applications in B2B sales are less 
applied at the current stage, but mostly in the customer service process. The interviews have 
shown that the usage of ML-applications is possible within all steps of the sales process and 
enhances its overall efficiency and effectivity in terms of time, costs and quality. Furthermore, 
tasks which increase the efficiency of the sales department through ML applications are 
outlined. By applying ML within the B2B sales process, the daily work of sales representatives 
can be facilitated, which ultimately could not only have a positive impact on customer 
satisfaction, but also on employee commitment leading to competitive advantage in the price 
intense environment of the pharmaceutical industry.  
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O presente estudo foca-se na possível importância da Aprendizagem Automática no serviço de 
vendas B2B em Empresas Farmacêuticas. Representantes de vendas responsáveis por uma 
grande variedade de actividades, afectados pelas demoradas e longas tarefas. 
Esta dissertação examina o potêncial da Aprendizagem Automática nas vendas B2B a fim de 
facilitar as tarefas diárias dos representantes de vendas, e de melhorar ainda todo o processo de 
vendas. Os resultados são obtidos através de uma pesquisa qualitativa baseada em 10 entrevistas 
com AI-experts, consultantes farmacêuticos e representantes de vendas, assim como fichas de 
dados provenientes de artigos e relatórios. 
Os resultados revelam que, em comparação com outros departamentos, a aplicação da 
Aprendizagem Automática em vendas B2B são actualmente menos aplicadas, sobretudo no que 
diz respeito ao atendimento ao cliente. As entrevistas mostraram que o uso da Aprendizagem 
Automática é possível em todas as fases do processo de vendas sendo que melhora toda a sua 
eficiência e efetividade em termos de tempo, custos e qualidade. Posteriormente, as tarefas de 
vendas mais eficientes dentro das farmácias estão estabelecidas; pelo que, a introdução da 
Aprendizagem Automática dentro do processo de vendas B2B poderá facilitar e, inclusive, 
melhorar o trabalho dos representantes de vendas, sendo que esta otimazação poderá, por 
conseguinte, não só ter um impacto positivo na satisfação do cliente como também no 
compromisso dos empregados originando, desta forma, uma vantagem competitiva face ao 
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1 CHAPTER 1: INTRODUCTION  
1.1 Relevance and problem statement 
In the recent advent of emerging technologies and a highly competitive environment, digital 
transformation and disruptive technologies are often significant game-changer (Saar-
Tsechansky, 2015). Concurrently, Internet of Things- (IoT), Artificial Intelligence- (AI), 
Augmented Reality- (AR), cloud-computing- or robotics – applications gather incredible 
amounts of data within a company.  
Thus, an effective information system, including the storing and processing of the data as well 
as the derivation of new value-added business models, are the real game-changer for 
enterprises. Nowadays, new technologies might outperform humans in the sense that they 
analyse data much faster. Given that fact, they gather more information and derive a way more 
results and models from it than a human can do (Bhardwaj et al., 2017). One of these techniques 
is Machine Learning (ML) utilizing structured and unstructured data to elucidate how to 
generate hidden insights and prediction models (George et al., 2016).  
By that, it focuses on the study of organizations, properties, and data analytics and their role in 
inference (Dhar, 2013). ML is no longer subject to the creativity and imagination of the media 
industry. Nowadays, it is one of the “hottest topics” in the technology sector evolving from an 
out-of-favour sub-discipline to a leading-edge frontier of research (Lewis and Denning, 2018).  
When Google’s Alpha Go algorithm beat the Go world champion in 2016, it became apparent 
that ML will shape the future. Looking at today`s voice or image recognition software like 
Alexa and Siri, it is evident which significant impact ML self-learning capabilities will have on 
people’s future daily lives. From a business perspective, ML applications can be implemented 
throughout the entire value chain within a company. Especially in highly competitive industries 
as pharma’s, ML application might facilitate the procedures of particular business units 
significantly on the one-hand side but might also create competitive advantage through process 
optimization (Burgess, 2017).  
Given the fact that a various researches deal with the improvement of ML algorithms from a 
technical point of view, less academic literature investigates ML from a business point of view. 
By evaluating the impact of ML enabled technologies on sales activities within pharmaceutical 
companies (pharma’s), the underlying study intendeds to evaluate ML-enabled technologies 




1.2 Objective and research question  
The underlying dissertation deals with the late-breaking technology ML. The purpose of the 
study is to contribute to the stream of research on ML, especially on the impact on the B2B 
sales process in pharma’s.  Hence, implications of how and where to implement ML within the 
sales operations may be derived. By evaluating the developed solutions, results will be 
generated so that statements about the degree of efficiency enhancements through ML can be 
obtained. Hence, the following research question was derived:  
Furthermore, the research question intends to provide an insight into which fields of the B2B 
sales service may be affected by ML and thus influencing the business operation process. By 
matching Ml enabled technologies with respective sales tasks an indication will be derived 
which estimates the sales activities with the highest impact on the efficiency ratio increase 
within the sales department, supported by ML technologies. Moreover, the study enables a 
future outlook on how to use ML applications in order to maximize the outcome of the sales 
process. However, the scope of the thesis is restricted to ML in pharma’s, from a sales point of 
view. Accordingly, the generated insights will be applicable for managers analysing which 
processes have the highest potential to be enhanced by ML. That is why, in this dissertation, 
strategic implications from ML will be more significant than the technical deployment of ML. 
1.3 Outline 
Fundamental education on ML, its concepts, challenges, and risks are covered in the first part 
of the dissertation. This section provides the reader with a deeper understanding of ML and its 
enabled applications/ functions.  Besides, investigations on the pharmaceutical industry and its 
challenges are made aiming to understand the market conditions and the pharmaceutical 
environment. Afterward, a definition of sales, the sales process, and KPI’s are associated with 
identifying first interfaces between ML and sales. Subsequently, the reader will be able to 
answer the following questions after the first chapter:  
• What are the capabilities of ML?  
• Which functions and technologies may be enabled by ML through these capabilities?  
• What are the characteristics of the pharmaceutical industry? 
Research Question: 
How can Machine Learning-enabled functions and applications maximize the efficiency 
and effectiveness of the B2B sales process for Pharmaceutical Companies in the future? 
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• What are the main tasks of sales representatives, and how is the sales process structured? 
• What are the KPI’s which determine an efficient sales process? 
• Where are ML technologies implemented within pharma’s?  
The second part of the dissertation is mainly based on in-depth interviews with ML experts and 
sales experts. The purpose of the interviews with sales representatives is to identify the decisive 
challenges in the current B2B sales process as well as getting an overview of primary 
responsibilities and performance indicators. The interviews with ML experts intend to identify 
the potential of ML-enabled functions and technologies. Thus, at the end of the dissertation, 
significant possibilities for efficient sales process optimizations through ML-enabled 
applications and features may be derived.  
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2 CHAPTER II: LITERATURE REVIEW  
This chapter provides a review of existing literature on the primary research field: Machine 
learning and gathers information about the pharmaceutical industry and sales operations.  
2.1 Machine Learning  
The subsequent chapter aims to define and classify ML in the field of data science. Moreover, 
ML-capabilities and enabled functions/ applications will be summarized.  
2.1.1 The basic concept of ML ordinated from AI 
ML is a subcategory of AI, allocated in the field of data science (Puranam et al., 2018). The 
first coined definition of ML was established in 1959 by Arthur Samuel (1959) defining ML as 
the ability of computers to learn independently without being explicitly programmed. In that 
sense, ML is a mathematical computer-based method enabling machines to learn for themselves 
while executing tasks (Cui. et al., 2006) and gain valuable insides on essential data (Akerkar, 
2014). To do so, ML requires an algorithm to extract useful insights from data focusing on 
adjust, retain, and update the algorithm based on gathered experiences (Cooper, 2018). The 
outcome of the learning process may be measured as the comparison between past and current 
behaviours rather than on real knowledge generated (Willens et al., 2016). ML applications are 
commonly used when structured, and unstructured data are too complicated for humans to 
describe analytically, but enough sample data - such as sensor data, pictures, or texts - is 
available. In that sense, ML may support computer models to identify patterns, shapes or 
designs in these existing data and thus, utilize these pattern to determine predictions and 
interferences to support the decision-making process in companies, even without human 
guidance and explicit reprogramming of the algorithm in future (Teodorescu, 2017). ML can 
be divided into three types of learning, namely, supervised (Cooper, 2018), unsupervised- 
(Luckert and Kehnert, 2016), and reinforced learning (Dey, 2013).  
Supervised learning is a learning process that consists of a training dataset containing input 
variables and a given number of correct output variables. Input variables are external 
information in the form of attribute variables or metadata, while output values might be specific 
labels of class attributes (Luckert and Kehnert, 2016). An algorithm analyses the training data 
and produces an inferred function identifying errors and predict which label to give to 
unlabelled data (Kotsiantis et al., 2007). An example of supervised learning are regressions, 
where the algorithm receives input and predicts the value of the output. 
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In comparison to supervised learning, unsupervised learning tries to discover hidden structures 
in unlabelled data (Das et al., 2015). Access to output variables and therefore, the machine 
needs to discover the data individually trying to find structures and patterns on their own. 
(Bhardwaj et al., 2017). Thus, the experience is not necessary (Luckert and Kehnert, 2016).  
Reinforced learning follows a trial and error approach ought to take actions in an environment 
to maximize a notion of long-term reward (Das et al., 2015). The algorithm behind learns from 
negative feedback and is only provided with positive or negative reward values for training 
(Portugal et al., 2018).  
Table 1: Overview of ML algorithms with particular techniques (adapted from Luckert and Kehnert, 2016). 
Even the three types of learning are beneficial for structuring ML in this paper; they overlap 
e.g., semi-supervised learning which uses unlabelled data to complement labelled data (Jordan 
and Mitchell, 2015). Deep learning (figure 1) encompasses all three described learning-types 
of ML (Skansi, 2018). By exposing multi-layered artificial neural networks algorithms to vast 
amounts of data, DL provides more precise and complex pattern discovery and feature learning 
and thereby represents a scalable version of ML (Long et al., 2018). 
Figure 1: Classification of ML within the field of data science (own representation based on Puranam, 2018). 
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2.1.2 Machine Learning adds value to the company’s overall performance  
Despite the high interest in ML applications in magazines and online forums, primarily 
investigations in ML applications/ features evaluations from a business point of view are not 
established topics in the academic literature. A high amount of researches deal with the 
development and testing of new ML-algorithms (Long et at., 2019). The purpose of these 
studies is to enhance the algorithm's preciseness and accuracy. Fewer papers focus on the 
connection between ML technologies and their efficiency process outcomes for particular 
business units. However, studies reveal that ML-enabled technologies have to potential to 
support the overall outcome of companies (Provost and Fawcett, 2013). Interestingly, 
companies using ML strategies in their operations are on average 5% more productive and 6% 
more profitable than their competitors (McAfee and Brynjolfsson, 2012; Brynjolfsson et al., 
2011), mainly through cutting costs in data collection and analyses accuracy (Teodorescu, 
2017). Thus, ML capabilities magnify the company's operational processes in terms of 
efficiency and effectiveness (Rudin and Ustun, 2018). Subsequently, from a business 
perspective, the main benefits of ML applications can be divided into three different value areas 
(Cui et al., 2006; Burgess, 2017). 
1) Customer satisfaction/ centricity elevates customer service and thus enhances profit 
streams 
2) The enhancement and development of processes and operations within a company 
lead to cost- reductions, -avoidance, and -compliance 
3) Valuable insights into data lead to risk & loss mitigation as well as revenue leakage 
mitigation 
In order to achieve the superior company objects, aptitudes of ML have to be identified.  
2.1.3 Machine learning capabilities 
In the academic literature can be found eight different capabilities (Akerkar, 2014; Burgess, 
2017) of ML (see table two).  The first four capabilities are related to capturing information. 
The focus is on the transformation of unstructured data (picture of a drug) into structured data 
(drugs name). Thus, patterns and relations in massive data sets consisting of hundreds of 
variables can be recognized. NLU, prediction, and optimization endeavour to understand 




Table 2: Overview of ML capabilities (own representation adapted from Burgess, 2017). 
As illustrated in table 2, no clear affiliation of the particular ML capability with the appropriate 
ML approach exists. Mostly it depends on the individual objective, and the way data are 
selected.  Based on the capabilities of ML, the following four applications are mainly discussed 
within the academic literature, namely Robotic Process Automation, Prediction and 
Forecasting, Natural Language Processing, as well as Robotics and bots (Burgess, 2017). 
2.1.4 Machine Learning enabled functions and applications 
Based on the described capabilities, this study centres on the four designated applications for 
ML-algorithms because they have seen as the applications with the highest potential for 
implementation within the sales unit. In general, ML-capabilities cannot be assigned to one 
particular ML-function. However, within an organization, ML-functions and applications can 
enhance the entire data management process by intelligently preparing cleaning and joining 
data from different sources (Zhou, 2017). Furthermore, it enables real-time decision making. 
By that, possessing information anytime available on all devices is guaranteed (Forbes, 2017).   
2.1.4.1 Robotic Process Automatization (RPA) 
Robotic process automatization mainly follows the ML-capability of optimization and utilizes 
software to automate rule-based tasks at a scale that was performed by humans before 
(Accenture, 2016). It evolved from undertaking a repetitive duty like checking invoices and 
travel expenses of single users to automate business rules and orchestra robots to address large 
volumes of work (Hallikainen et al., 2018). Thus, it simplifies an operational scaling within a 
company by enhancing speed (process cycle time), quality while simultaneously decreasing 
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complexity and error susceptibility (less transactional errors) (Hallokainen et al., 2018; 
Accenture, 2016). Due to low implementation costs and a high expected return on investment 
(ROI), it can be seen as an effective and inexpensive way of process automatization enhancing 
profit streams and customer service (Willcocks et al., 2017). RPA can be assessed as the 
underlying technology for predictions, NLP, and robotics/ bot functions. 
2.1.4.2 Prediction and Forecasting 
Prediction and Forecasting functions mainly follow search or clustering capabilities (see table 
two). From a company's point of view predictions can be used to give an overview over sales 
demands, individual actions of customers or employees, customer choices but also to forecasts 
the likelihood of events (George and Haas, 2014). Even rare event modelling is uncommon in 
management researches ML enables, for instance, organizational responses to disasters, 
mapping probability of failure, or assuming risk behaviour. These results can be displayed in 
apps or computer software (Van der Vegt et al., 2015). Through the self-training of the 
algorithm, ML methods can produce superior predictive accuracy compared to traditional 
methods like linear regression or logit models (Baiari et al., 2016). The recent challenge of 
prediction and forecasting functions is to maximize the accuracy, determine missing variables 
(features) and consistencies of the model (Puranam et al., 2018). Thus, it will be an essential 
function for businesses in order to position themselves in the market and ensures safety and 
precise long term planning.   
2.1.4.3 Natural language processing (NLP) 
NLP utilizes many different techniques for interpreting and understanding human language, 
ranging from ML to DL (Akerkar, 2014). It is mainly divided into image-/ and voice- 
recognition capabilities (Burgess, 2017). Ideally, the algorithm behind analyses large amount 
of texts and words, understand them intending to reply to questions automatically. By speech-
to-text as well as text-to-speech extractions discussions with human beings might be enabled 
(Nugues, 2006). Hence, NLP can identify emotions behind words and expressions. Thus, in 
future responses related to the contemporary behaviour of customers can be made and triggers 
for positive buying decisions might be identified (sentiment analysis).  
2.1.4.4 Robotics and Bots 
Robots becoming more and more discussed topics in modern times. Robots use input data from 
different sensors and combining their voice, image, NLP and optimization capabilities in order 
to come up with the most appropriate response to the action by continuously improving its 
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algorithm (Burgess, 2017). For that sake, the robot requires unstructured data, and thus, ML 
capabilities like search or text identification are transforming the data well-structured to the 
robot. Despite the fact, that the technology can overhaul transactional work at a 50% lower cost 
(compared to humans), it also can enable businesses to operate 24 hours per day for 356 days 
per year (Accenture, 2016). 
Furthermore, the robot can execute the tasks independent from vacations or unforeseeable 
diseases (Burgess, 2017). Applications of these robots/ bots already exist in various fields like 
autonomous driving, manufacturing robots, game bots, or service bots (Torralba et al., 2008). 
Especially the latter one in from of catboats aiming to greet and review customer requests can 
be a significant trend in the field of sales and customer service.  
  
A more in-depth insight into the value and usage of ML-applications within the pharmaceutical 




2.2 Pharmaceutical Industry 
The subsequent section will provide an overview of the pharmaceutical industry, its challenges 
as well as the typical sales process within pharma’s. 
2.2.1 Market Structure and Market Size 
Pharma’s represent a firm that is involved in R&D, manufacturing, marketing/sales of drugs, 
and biologicals (International Trading Administration, 2010). Traditionally, pharma's core 
business was the development of new drugs (e.g., generics, orphans, prescription drugs) to treat 
diseases and make a substernal revenue out of (Denoon and Vollebregt, 2010). Nowadays, 
pharma's shift the focus toward the development of affordable medicine (applied budget limits 
that deny patients access to innovative therapies) and technological changes in, e.g., drug 
discovery and the integration of new digital tools in the business model (Capo et al., 2014). 
According to the estimates of the Pharma Market research report (2018), the global 
pharmaceutical market will be set up to grow at 6,5%  per year (CAGR), reaching $1,06trn by 
2022. Not only the orphan drug-market is to almost double until 2022 up to $209bn, but also 
generics and other prescription drugs contribute $112bn and $739bn in 2022 to the overall 
growth (Deloitte, 2018). Drivers for the high pharmaceutical consumption are legal, 
technological, environmental as well as economic changes in the environment e.g. faster routes 
to markets, compelling market access value proposition, rapid global population aging, 
anticipated growth in chronic disease, urbanization, income raise, higher governmental 
expenditures in pharmaceutical industry and utilization of disruptive technology as AI, or IoT 
(ITA, 2016; Pharma research Report, 2018; McKinsey, 2018). Nevertheless, the industry 
remains a low concentrated market, although highly competitive. Considering the fact that a 
market entry requires huge investments, e.g., for drug discovery, entry barriers are high. 
Consequently, the market is dominated by large multinational enterprises as Roche, Novartis, 
Pfizer (Boldrin and Levin, 2005). Moreover, these companies understand how to commercialize 
so-called "high-value blockbuster drugs" by a strong workforce that established powerful 
customer relationships (Raja and Sambandan, 2015). In that sense, the sales and marketing 
department is crucial within pharma's in order to stay competitive and guarantee a solid base 
for future revenues.  
2.2.2 Challenges of the Pharmaceutical Industry 
The most important challenges pharma's are facing are the competitive environment, reduced 
drug pipelines, the expiration of multiple patents as well as changes in customer preferences 
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(Wenzel, 2014). Particularly, the expiration of many patens started in 2010 is remembered as 
"patent cliff" phenomena punishing pharma's heavily (DeRuiter, 2012). For instance, famous 
blockbuster drugs, e.g., Rituxan, Humira, and Avastin lost their rights and patent status between 
2014-2019, diminishing profits, and setting price pressures on pharma's (Fernandez et al., 
2012). The development of new drugs requires a good understanding of the environment, the 
customer, as well as the facilitation of patient access (McKinsey, 2018). The second challenge 
is the decline in R&D productivity so-called "productivity paradox" (Litinski, 2010) based on 
the adherence to old discovering and developing processes (Syrovatka, 2011). Expositions in 
the availability of healthcare data and software & hardware enhancements presuppose the 
implementation of an ML strategy fostering productivity concerns (BCG, 2019). Thus, within 
the pharma's obsolete management culture, mental methods, and strategies have to be 
overcome, implementing new ways of doing business (PWC, 2019). A new mind-set is 
unavoidable in order to foster the synthesis of new technologies and digital business models. 
Given the fact that the industry has remained oddly unaffected by digital transformation, also 
the B2B market lacks behind in terms of automatization (Asare et al., 2016). Price competition 
triggered through the development of new drugs is another challenge the industry is facing 
(Deloitte, 2018). In that sense, smart and automated marketing and sales strategies need to be 
realized in order to intensify customer service, satisfy and retain the clients. Along with this 
come regional/ governmental restrictions in terms of drug advertisement, pricing, and 
promotion, which require strong personal customer interaction.  
2.3 Sales in pharmaceutical companies 
The subsequent section deals with the B2B sales process within pharma’s and its activities. 
2.3.1 The sales process and its activities 
Although several authors investigated researches in the field of sales, there is no clear 
conceptualization of the sales process and its related tasks in general (Williams and Plouffe, 
2007). However, the most widely accepted paradigm in the sales disciplines until today evolved 
by Dubinsky (1980/1981) consisting of seven different sales steps that apply to pharma's 




Figure 2: The sales process in seven steps (adapted from Moncrief and Marshall, 2005; Moore et al, 2015). 
Pharma’s operate in both markets, B2B and B2C.  The target customer group (B2B) are 
hospitals, pharmacies, private cliques, wholesales, and doctor offices. The purpose of the 
salesforce is to build up long lasting relationships with these customers. In that way, more 
complex and costlier deals can be closed. Furthermore, B2B sales are stronger, embracing 
customer education, product demonstrations, and customer service, while a couple of 
stakeholders are part of the sales process. That necessitates a data-driven salesforce that is 
updated in real-time and understands each decision of the customer's purchase. For that sake, 
new technologies and digital real-time tools and channels can support the work of the salesforce 
(McKinsey, 2018). The strong relationship focus underlines the thesis that sales B2B 
representatives are the key players in pharma's and determine its success (Shi et al., 2017). 
Dixon & Tanner (2012) determine sales as "the phenomenon of human-driven interaction 
between and within individuals/organizations in order to bring about economic exchange within 
a value-creation context." In pharma's the salesforce contributes profoundly to the financial 
balance of the companies by nourishing revenue and profits (Zolter et al., 2009). For that cause, 
they need to review and analyse market trends, recognize customer needs, and become the 
contact person in the product development process and its launch (Judson et al., 2009). 
Secondly, the sales representative may be viewed as a business agent actively "push" the 
product or service (Zoltner et al., 2008) toward each potential customer (George and Haas, 
2016). That italicizes the fact that the sales team is the prime source for customer information 
(Pelham and Lieb, 2004). By connecting both sides of the market (Stan et al, 2012), the role of 
the salesforce enveloped from a spokesperson of the selling firm to a consultant for the buying 
firm (Sheth and Sharma, 2007). Nonetheless, communication and collaboration with the other 
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departments are essential for the salesforce (Lynn and Akgun, 2003), requiring strong personal 
interaction skills (Ingram et al., 2012). Within pharma's, the salesforce is obliged to achieve 
ambitious goals (Judson et al., 2009). Thus, high customer involvement and engagement in 
multiple key accounts are essential success factors. These tasks are time-consuming and require 
strong organizational skills (Mantrala and Albers, 2010). Therefore, a sales rep churn can harm 
pharma's through information- and client/ contact losses (Shi et al., 2017).  
2.3.2 Sales key performance indicators 
Key performance indicators (KPI's) can be defined as physical values (Gosselin, 2005) which 
measure the performance of processes and operations within an organization (Matsuo et al., 
2013).  
Anderson and Oliver (1987) provide the first concept of sales performance as the evaluation of 
sales forces based on sales outcomes (e.g., sales units, revenue, market share, new accounts, 
profitability) as well as sales behaviour (teamwork, effective communication). Within pharma's 
salesforce performance can be measured in terms of monthly sales, up- and cross-selling 
activities and subsequently, monthly sales growth/ closing ratio (Ramarajan et al., 2017). Since 
the sales are often closed during phone calls, monthly email- and phone call-rates are an 
additional performance indicator. The number of prospecting activities like product meetings/ 
demos as well as the final closing rate are additional pointers for the sales reps completion 
(Zallocco et al., 2009). For pharma's clients, information is the primary source for further drug 
development. 
Consequently, the salesforces can be assessed via their customer engagement level, which 
implies an evaluation based on their client know-how and information related to market and 
competitor environments.  In case this information can automatically be tracked, through ML 
algorithms, churns and other exits can be successfully caught up (Jaramillo et al., 2007).  
2.4 Machine Learning in Pharmaceutical Companies 
The subsequent sections will connect ML technology and pharma's. At the recent stage, several 
authors investigated ML applications within the value chain. R&D (Christensen et al., 2017), 
production (Liu et al., 2018) and logistics (Jordan and Mitchell, 2015) were the focal points of 
their analyses. The underlying study attempts to complete the topic by examining ML in sales 
and its impact on the efficiency within. 
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2.4.1 An efficient sales process 
Efficiency is referred to an input-output ratio or comparison to reach a particular goal with 
minimal outlay and thus, directly effecting the companies margins and profits (Ostroff and 
Schmitt, 1993).  In terms of sales performance, this ratio can be explained as sales outcomes in 
comparison to sales inputs described as calls, demos, emails, or letters (Ingram et al., 2002). In 
order to improve the input ratio, technologies can help to save time and enhance key-account 
management performance. Moreover, costs efficient tools can optimize e.g., customer-calls 
quality by RPA solutions (Zallocco et al., 2009). Compared to efficiency, effectivity is more 
related to the sum of total sales outcomes of all sales units, rather than the performance of a 
person within the firm (Anderson and Oliver, 1987). It goes along with the organizational 
mission and develops strategies in terms of gathering insights and understanding. Examples for 
that can be, the identification of target markets, customer call patterns, sales product portfolio 
strategies, competitive positioning (Zallocco et al., 2009). Thus, it meets ML primary capability 
of understanding and discovering hidden patterns.  
2.4.2 An efficient ML process 
To foster efficiency and effectivity within sales ML has to be integrated successfully inside the 
company's culture as well as within the company's strategy. That is why relevant stakeholders 
refer to understand the four ingredients of an efficient ML-strategy, namely algorithm/ model, 
data, computation/ training, and judgment/ optimization (Peukert, 2019):  
Algorithm/Model 
Approaches to choose to the right algorithm are broad because no transparent classification 
scheme for algorithms exists (Long et al., 2019). Following the main target of the algorithm 
labelling, clustering, and categorizing data and identify hidden patterns or similarities within 
the dataset. Thereby, over-fittings can be reduced modifying a much more complex dataset, 
find undiscovered interactions, reduce prediction errors, and cross-validate the results 
(Puranam, 2018). Thus, the further enhancement of the algorithm is the real competitive game-
changer for pharma's in the future (Obermeyer and Emanuel, 2016).  
Data/ Computation/ Training 
The major challenge within business units is not the implementation of machine learning 
applications into the IT-infrastructure of the company. A successful data management strategy 
as a baseline of an effective machine learning system is illustrated in figure 3. Only an efficient 




Further development and adaption of the algorithm to achieve more precise results are one of 
the main challenges. That requires a constant incoming data flow as well as the knowledge 
about interpretations and adapting algorithms input variables. Besides, ML applications are no 
substitutes for the researcher's human judgments. While ML algorithm can discover robust 
patterns in data, conceptualize and measure (select) them, the explanation (theorizing/ 
reasoning) (Sheperd and Sutcliff, 2011), remain mostly human prerogatives (Puranam et al., 
2018). 
 
Figure 3: Overview for an efficient data management process for ML applications (adapted from Akerkar, 2014). 
2.4.3 The use cases of Machine Learning within pharma’s 
Within an organization, ML-functions and applications can enhance the entire data 
management process by intelligently preparing cleaning and joining data from different sources 
(Zhou, 2017). By integration ML algorithms into the business processes, the decision-making 
process will be facilitated by real-time information support. By that, having information 
anytime available on all devices is guaranteed (Forbes, 2017).   
2.4.3.1 R&D and Manufacturing 
Drug Discovery/  
ML applications for drug discovery and manufacturing may be predictions of success rates 
based on biological factors. Moreover, precision medicine to identify alternative therapy path 
often involves an unsupervised learning approach. (Ajani et al., 2018).  
Disease Identification and Diagnosis 
Moreover, investigations in the field of disease identification (e.g., cancer) prevention and 
curing have dramatically emerged during the last decade (Kerestely et al., 2018). Thus, ML can 
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help to reduce the rising drug discovery costs and support the doctor-patient relationship by 
enabling personalized treatments and behavioural modification for patients (Bhardwaj et al., 
2017).  
Clinical trial research 
Identifying through prediction candidates for clinical trials would result in smaller, quicker, and 
fewer trials overall. Besides, prognostic analytics can be drawn on a much more extensive range 
of increasing data precision (McKinsey, 2018). Hence, finding the best sample size increases 
the efficiency or reducing data errors are the main applications in the field.  
Smart Electronical Health records 
Document classification (emails) and character recognition are essential ML-applications in 
pharmaceutical companies and facilitate the employee's organizational outlay.  
2.4.3.2 Logistics/Supply Chain 
Through forecasting, the demand better, ML service level and inventory costs can be reduced. 
Collaboration synergies between supplier networks might be identified and enhance the supply 
chain environment by e.g., predict the transportation and material costs or estimate missing 
capacity information. 
2.4.3.3 Sales and Marketing  
Machine Learning in form of web or mobile analytics tools to predict individual actions, 
customer choices (George and Haas, 2014), customer purchases (Cui et al., 2006) or the 
likelihood of an event (Van der Vegt et al., 2015), are becoming significant for companies (Cui 
et al., 2006). Hence, the customer journey could be improved, triggers for buying decisions may 
be identified, and therefore sales qualified leads enhanced. Moreover, predictions in fields of 
individual risk propensity, avoidance behaviours, or risk mitigation are standard (George and 
Haas, 2016). Moreover, Chabot's, for instance, ensures a 24h/7 service offering the best answer 
to customers while analysing their response. Thus, ML and data analytics fostering sales 
productivity and drive double-digit sales without future investments and sales team changes 
(McKinsey, 2018).  
2.4.4 Challenges and Risk of ML applications in sales  
The first challenge inherent with the implementation of Machine learning in companies is 
access to a vast amount of sensitive data which subject to privacy concerns (Goh et al., 2019). 
Thus, ethical and regulatory restrictions have to be complied with at each stage of the data 
collecting process (European General Data Protection Regulation) (Vayena et al., 2018). 
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Another risk of ML algorithms is that it is a so-called "black box" system because thousands of 
complex rules are associated with the ML model (Long et al., 2018). Thus, the "rules engine" 
should be visible in order to let users understand the reasoning behind the results (Zhou, 2017). 
In that sense, the management of a company has to ensure the technology's understanding 
within the business unit. Otherwise, the technology will be employed mistakenly, and 
employees do not comprehend the reason behind the technology leading to a negative impact 
on its efficiency ratio (Goh et al., 2019). Moreover, a convenient education regarding 
technological changes is essential to achieve acceptance of the ML solutions throughout the 
salesforce overcoming the main fear of replacement (Zhou, 2017). 
  
However, literature about the benefits of ML applications exists on a full scale, but a guideline 
on how to maximize efficiency in the sales process in pharma's through ML does not exist at 
this time. That is why the underlying dissertation endeavours to form a model that connects 
sales processes within pharma's with the right ML-enabled function/ technology and measures 






3 CHAPTER III: METHODOLOGY 
The subsequent chapter carefully examines the methodological steps taken during the given 
research process and explains the collected data, including qualitative results.  
3.1 Research Method and Strategy 
Researches in the field of ML from a managerial perspective is limited, as the technology is 
continuously progressing and the environment involved continually changing. That is the 
reason why there is a great room to add significant insights to the ML concept. The objective 
of the study is to recognize which technologies are enabled by ML. Afterward, the paper should 
give an assumption of how to utilize them in order to increase the efficiency of the sales 
department. In order to come up with reasonable approaches, the dissertation follows an 
exploratory approach. Following such an approach, the gathered insights will enhance the 
perception of an obstacle profoundly, seeking an in-depth description of a defined problem 
(Gephart, 2004). Moreover, qualitative methods are mainly applied for the exploration of a little 
known subject of research (pharma's) as well as for supplementing and validating existing 
literature (Lang, 2010).   
The conducted research is based on two methods. (1) The collection and inquiry of secondary 
data as well as (2) primary data (figure 4).  
Secondary data 
 Secondary data in terms of online-articles and publications were convened to provide a 
fundamental overview of topics like ML, the pharmaceutical industry, B2B vs. B2C, and the 
tasks throughout the sales process. More specially, investigations on the technologies ML 
Figure 4: Overview research strategy (own representation, 2019). 
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enables have to be made in order to discover tasks and operations of the sales process can be 
affected by ML. Besides, a profound insight into the sales process is reasonable because "sales 
efficiency KPI's" have to be identified to compile recommendations on how to maximize 
efficiency throughout the sales process.  
Primary data 
The primary source of qualitative research is qualitative data and inductive theorizing (Bansal 
et al., 2018). Subsequently, qualitative data can be conducted through the collection of 
empirical materials e.g., case studies, personal experiences, interviews, or artefacts (Denzin and 
Lincoln, 2000). Inductive theorizing relies on logical reasoning based on former insights with 
the aim to abstract and generalizes new knowledge from the data (Bansal et al., 2018). One type 
of qualitative research is qualitative in-depth interviews which are beneficial in terms of ease 
and cost-efficiency (Given, 2008). The goal of qualitative interviews conducted during the 
research with ML and pharma sales experts in the production of new content benefiting from 
the fact that the interviewee's experiences, ideas, and impressions are documented and 
considered (Alvesson, 2003). 
Moreover, the interviews are often loosely structured and open to content the interviewee 
considers as essential. Rowley (2012) describes qualitative interviews as the collection of 
"facts" and gain insights as well as an understanding of the interviewee's experiences, attitudes, 
processes, predictions, and opinions. Hence, the purpose is to go below the surface and explore 
new undiscovered ideas and insights (Britten, 1995). However, regularly, the type of in-depth 
interview can be classified based on their structure lever (Rowley, 2012). The three common 
types are structured, unstructured, and semi-structured interviews, all following an explanatory 
approach (Van Puyvelde, 2018).  
Semi-structured interviews  
This paper follows a semi-structured approach that empowers the researcher through a mix of 
rigid structure and uncertainty to go deeper into relevant topics (Ackermann and Rockmann, 
2002). A couple of neutral open-end questions are predetermined with an open result. Thus, the 
responded has leeway in terms of flexibility and freedom of the answers (Given, 2008). The 
right amount of interviews is controversially discussed in the literature. While the 
anthropologist Spradley (1979) recommends conducting between 25 and 30 interviews, 
business researcher McCracken (1988) proposes to collect eight, while Glaser and Strauss 
(1967) do not mention a specific number but suggest to gather interviews until a state of 
theoretical saturation is reached. For that sake, the author decided to collect around 8 interviews. 
Concerning the structure of the interview Gubrium et al. (2012) recommend to start the 
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interview with two to three introductory icebreakers, followed by transition questions five to 
eight main questions. The main questions are related to the research question and should be the 
focal point of the interview. To conclude, valuable interview insights will be summarized 
(Patton, 1987). 
Data Collection 
The participants of the interview were contacted via E-Mail, LinkedIn, and personal contacts. 
Before the interview, all of the participants were given an explanation of the research objective, 
the research question, methods of data analysis, and reassurance about confidential issues. In 
total, 8 participants were interviewed for 45 minutes.  
Participants 
 The participants of the survey composed of two different target groups. Firstly, ML experts 
were interviewed, mostly professors or consultants with a computer science background or 
experience in the field of AI. The second group consists of sales representatives and experts 




Table 3: Overview of interviewees. 
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4 CHAPTER IV: ANALYSIS OF THE IMPACT OF ML ENABLED 
TECHNOLOGIES/ FUNCTIONS ON THE B2B SALES PROCESS OF 
PHARMACEUTICAL COMPANIES  
The subsequent chapter summarizes the semi structured interviews with Machine Learning 
experts and sales expert. Throughout the chapter a model will be derived connecting the sales 
process and its tasks with particular machine learning functions and applications.  
4.1 The sales within pharmaceutical companies  
This section will sum up the most prominent trends within pharma’s aiming to come up with a 
verified sales process form the theory rose at the end of chapter 4.1.3. 
4.1.1 The main challenges within pharma’s are diversified 
The insight gathered through the interviews corresponded with the insights from the literature 
review.  
The most influential challenges within the pharmaceutical industry address digital 
transformation lack (interview 6), missing technological know-how (interview 8), high R&D 
costs (interview 8) as well as long time to market cycles (interview 7). Pursuing a digital 
approach in order to implement new technologies and enhance operations is a novel challenge 
pharma’s have to deal with (interviewee 6). Hence, most of the pharma's are driven by costs-
pressures rather than by their digital DNA. Pharma's turning their paradigm to concentrating on 
the access of new treatments to an affordable price for the end-consumer. For instance, Novartis 
– traditionally focused on vet medicine & generic drugs – specialized in the development of 
new affordable cutting edge therapies based on faster time-to-market cycles and fewer R&D 
expenses (interviewee 7). Another concern of pharma's is the high dependence on political, 
country-specific regulations, e.g., restrictions concerning the advertisement of drugs in 
Germany (interviewee 6). ISO norms and GDPR restriction and other fast-changing laws 
require a lot of flexibility and adaptions from pharma’s. Another example is the price pressure 
which permits only a small derivation from the original price set up (interview 8). The 
pharmaceutical industry is extremely competitive, as well as price-sensitive. That is why 
pharma's ought to uncover distinct methods to distinguish from their opponents. ML-
applications hold the potential to strengthen the company’s competitive advantage through 
process optimization (interview 7). 
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4.1.2 The main challenge of sales representatives is to reach individual performance 
goals  
The subsequent section implicates to identify the most significant pains and concerns sales reps 
might have during their daily routines. It will be essential to obtain a statement later, where to 
implement ML solutions.  
In general, the sales department in pharma’s is represented by the respondents as a very 
competitive and time-intensive department, frequently with claiming daily, monthly, and yearly 
goals (Interviewee 7, 8). One interviewee remarks as follows: 
“Sales reps traveling from one client to the other one from Monday to Friday. Once you don’t 
fulfil the goals, colleagues overtake the job for you with the result that you are going to be 
outperformed (interviewee 7).” 
Sales representatives are steadily operating under pressure and against the clock. Fast-changing 
product details and market situations hamper the salesforce work. Hence, it is challenging to 
keep up with news and real-time information for the end-customer (Interviewee 7). The 
competitive pressure also requires a new level of product complexity as well as a broadly 
diversified product portfolio. The sales staff can only overlook this complexity with the aid of 
digital tools accessing database, specifications, price lists, and discount rules in real-time 
(Interviewee 6). To build up long-lasting relations in the B2B market, credible information 
about the product portfolio for efficient customer support is a critical success factor 
(Interviewee 8). Another key challenge is to understand the customer by asking the right 
questions in a conversation and consult them whenever and wherever they require information. 
That is why detailed product specifications, a simple purchasing process, quick answers to 
questions, and prompt delivery are additional factors of success in the B2B sales market. 
Moreover, customers in the B2B market are also regularly driven by time pressure (Interviewee 
7). Therefore, short tailored pitch decks, short product demonstrations, and extensive 
communication skills are imperative for the salesforce in pharma's. The flexibility and 
enormous speed demand stable connection between client databases (CRM) and ERP systems 
in order to provide rapid information, e.g., on product delivery or product data (Interviewee 5). 
The interviews confirmed that performances of sales reps are measured in terms of sales 
calls/emails, conversation rates, and successful deals closed as well as up-& cross-selling 
activities (Interview 6). In order to examine and measure the performance, the salesforce is 
obliged to report and monitor their activities.  
“After an information exchange with clients (calls, emails, product presentations, etc.) the 




Another concern mentioned in the interviews is the lack of transparency. New digital tools and 
applications exist within the company, but nobody knows about it. That indicates that pharma's 
ought to enhance their communication channels as well as their employee training (Interview 
6). 
4.1.3 Sales steps and operations in pharmaceutical companies are inconsistent 
This chapter aims to illustrate the sales process and its particular tasks within pharma's as a 
foundation for chapter 4.2. The results inferred in this section are mainly based on inductive 
theorizing because most of the interviewees did not want to mention specific sales activities 
and tasks. 
Nevertheless, the insights deduced unveiled that the B2B sales process in pharma's cannot be 
lump surmised (Interviewee 8). Each company has its independent structure and organization 
follow different goals depending on its size, profits, and the number of employees (Interviewee 
9). In large enterprises, key accounts manage the sales, interactions, and relationships with each 
client. In smaller companies sales representatives are responsible for a couple of different 
hospitals, doctors and drug stores.  
In chapter 2.3.1, the sales process consists of seven steps. A different model was derived, which 
clusters the sales process into four principal sales categories and two ongoing sales phases 
(figure 5).      
Figure 5: The sales process in pharma's (own representation, 2019). 
The obstacle to Dubinsky's model was that individual activities could not be separated from 
each other because of no precise categorization. That is why packages where develop which 
can depart the phases more precisely. The distinction between the main tasks and support tasks 
is the time component. While supportive tasks are executed on a daily base, activities belonging 
to the main phases are often performed less recurrent.  
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1) Lead and Planning Phase 
The lead and planning phase is the starting point for further strategic decisions for the head of 
sales based on market, trend, and event analyses as well as forecasts. Based on those 
assumptions, future lead channels, and new customers may be recognized. Moreover, the 
forecasts and predictions provide new information on the future outlook and success rate of the 
particular drug. Thus, it is crucial for the setting of strategic goals. The more precise the tasks 
are performed, the easier it is for the sales department to determine reachable yearly, monthly, 
and daily sales goals. The phase terminates with the visualization of all required data to reach 
new customers (Interviewee 8).   
 
Figure 6: Lead and planning phase with related activities (own representation, 2019). 
2) Offering Phase  
After the lead and planning phase is finalized, the offering phase sets in. During that phase, the 
first customer contact is made. Real-time data (prices, products, and customer data) available 
at every point of customer interaction is a significant success factor (Interviewee 5). During 




customer interaction, it is necessary to understand the customer without losing information 
about their concerns and their preferences. During this phase, the salesforce offers a lot of 
customer-specific activities and tasks, e.g., protocolling, product presentations, pitches, and 
individual proposals based on the customer's input. The phase ends with the first feedback of a 
proposal draft (Interviewee 7).  
3) Closing Phase 
 The closing phase starts with the first customer feedback. The preparation of contract- and 
accounting documents, as well as the closing of the deal, are focal points.  Information about 
prices, delivery time, discounts, and the number of products or product modifications have to 
be gathered, summarized, and added into a CRM/ ERP system (Interviewee 5). Notably, price 
anticipations and discount rates determine the success or failure of a deal.  Most likely, the 
phase closes with the shipping and tracking of the drugs.   
4) After-Sales 
The after-sales services within pharma's are mainly based on permanent presence whenever the 
client requests information. This information can be specific company details, product-related 
issues as well as any other wishes the customer might have. Due to the high competition within 
the industry, fast and precise responses are significant because customer satisfaction and 
retention is the most critical factor for long-lasting relationships (Interviewee 8). Hence, the 
Figure 8: Closing phase with related activities (own representation, 2019). 
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collection of feedback is a success factor in order to retain the customer and increase the chance 
of closing further sales.   
5) Data Management 
Data management activities developed from underappreciated tasks to potential game-changers 
throughout the sales rep activities. Nowadays, data are gathered at any touchpoints within the 
sales process regardless of client interactions, conducted analyses, or the input from data into 
company-related systems. In pharma's, all actions need to be recorded, and thus, many data can 
be gathered (Interviewee 8). Despite ensuring IT-architecture and security, an automated 
dataflow provides the sales reps with relevant information and saves them time and manual 
effort. The enhancement of handling and working with these data on a daily base will boost 






Figure 9: After sales with related activities (own representation, 2019). 
Figure 10: Data management with related ongoing activities (own representation, 2019). 
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6) Relationship Management 
 The tasks included in the relationship management phase accompany the sales rep during their 
entire function on a daily base (Interviewee 8). Hence, high repetition potential, a high manual 
effort for data input and inefficient time management (e.g., screening and answering of e-mails, 
customer trip planning) deemed to be barriers in the daily routine of sales reps.  
4.2 Machine Learning potentials and challenges  
The subsequent chapter aims to identify the potentials of ML-applications and challenges. At 
the end of the chapter success factors of ML applications may be derived, and suggestions of 
ML-applicable tasks and processes will be given.  
4.2.1 The state-of-the-art technology ML has not reached its full potential in pharma’s 
yet 
There is an agreement among the interviewees regarding the status quo of ML-applications and 
functions. Machine Learning applications and functions are software that is trained through 
algorithms (statistical models, regressions). The intention is to support operations and processes 
throughout the entire value chain of the businesses, reflected by 80% of the interviewees 
(Interviewee 3). For instance, 4/5 ML experts discern the highest potential in the production 
line, while 3/5 mentioned logistics as the primary implementation field. The reason for that is 
higher upside potential in this field triggered by uncertain cost factors for companies 
(Interviewee 2). Nevertheless, all of the ML experts appraise ML and its functions/ capabilities 
in sales as a recent hot topic for companies fostering its competitive advantage through process 
optimization and automation. Interviewee 1 alludes this hypothesis in as follows: 
"As long as you can transform your data into numbers/ series of numbers, ML can be 
implemented everywhere. That is the case for all the data currently existing." 
Figure 11: Relationship management with related ongoing activities (own representation, 2019). 
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To become fundamental to more numerous companies, enhancements in the production of 
better and more broadly applicable algorithms for the foreseeable future are necessary 
(Interviewee 3). On the contrary, Interviewee 4 (2019) points out that the true potential of ML-
applications does not lie in the construction of new algorithms, but in the implementation and 
adaption of the algorithms already existing within the particular company-specific system. 
Although there is consensus about the growing relevance of ML, future developments remain 
tough to predict because the outcome is a black box. More and more ML solutions/ ML services 
will undoubtedly be offered to companies during the next years due to the media hype around 
the topic (Interviewee 2). Large pharma's have recognized the imperative to invest in new 
digital solutions. Novartis established a tech-hub in Barcelona which deals with AI applications 
and new apps. The challenge is to close the gap between employees who produce the algorithm 
and those who utilize the results (Interviewee 7). Recently ML-applications are commonly used 
to predict the outcome of special sales events, balance sheet figures, yearly sales rates, and the 
potential sales volume within big pharma's. Smaller pharma's companies, on the contrary, do 
not have the expertise and resources in order to realize an ML strategy quickly.   
4.2.2 Data Management as the key challenge of ML applications 
The majority of the interviewees' consent on data preparation and processing as the major 
challenge for companies (5/5 experts), followed by a lack of understanding (magic number code 
problem 4/5 experts) appearing in challenges associated with the correct usage and adaption of 
algorithms (4/5 experts) (figure 12). Solutions to overcome the divergence between 
mathematicians/ physicians, who develop the algorithm and business people who do not 
understand the logic behind the algorithms, need to be figured out by companies in order to 
develop a result/ customer-oriented ML strategy (Interviewee 5). After all, 3/5 experts 
highlighted legal restrictions concerning data digitization and compliance with regulations as a 
significant hurdle for companies. E.g., the Russian data protection policy is less strict, allowing 
e-health companies to gather and use data from central IT. Thus, pharma 'sin Russia can work 
on new drugs even before the international competitors recognized the future problem 
(Interviewee 1). However, when dealing with country specific data protection laws as well as 
data conformity must be proofed from the companies' side in order to guarantee a smooth 
utilization of ML applications (Interviewee 4). Misconceptions and inefficient utilization of ML 
applications are often spread out from top-management who want to foster innovation without 
fundamental knowledge on how to nail the challenge. Thus, many pharma's desire to implement 
solutions into their systems but do not even have the IT- architecture to set up efficient ML-
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strategies (2/5 experts). Cloud solutions and data warehouse strategies are striving to 
accumulate data within one system in order to ensure full transparency the data availability and 
storage. From these hurdles, success factors may be derived in 4.2.3.  
 




4.2.3 Success factors for an efficient usage of ML enabled applications  
Among the interviewees is a collective agreement toward the most decisive success factors. All 
of the interviewed persons (100%) highlighted the understanding of ML applications as the 
most significant future challenge, illustrated in figure 13. First of all, the management level of 
a company must be aware of this fact that the set-up of clear goals and its communication 
throughout the business units is essential. The way how the management educates and cultures 
their employees will significantly impact the ML-adaption throughout the company. Failure 
will result in black box phenomena (Interviewee 2). Thus, the applications cannot reach its full 
potential because e.g., mistakes will not be identified, and people cannot interpret the results 
(Interviewee 3). Thus, the model cannot be improved, which leads to the second factor of 
success, classical data science work (83, 3%) including gathering, training, balancing, and 
ironing out data. Analyses came up with the result that these tasks take 80% of the 
implementation time. The remaining 20% comprise the actual coding and building up the 
problem (Interviewee 1). A thriving ML-introduction also needs to be compliant with the 
implemented IT-systems and architecture considered as the sine qua non. The adaption of the 
developed algorithm is another key for an efficient ML-implementation, according to 66, 6% 
of the interviewed persons. Based on the company-specific needs variables within the algorithm 
need to be continuously updated, converted, and modified based on the anticipated outcome. 
Moreover, persistent training and optimization of the dataset denoting convey different layers 
(number input) into a number output of the algorithm between different domains. In order to 
reach the full potential of the algorithm, data collection over a specific period needs to be 
collected and transformed into numbers/ series of numbers. 66, 6% of the respondents jilted 
data access as a successor. Today on the on hand-side several databanks exist where the 
company's purchase data and collect various information about the customer. From a business 
perspective point of view, the cost and time components also matter in order to come up with 
an efficient and effective implementation strategy. Unlike the common sense of ML setups 
solely require a few data which do not require high purchasing investments. 
"A prototype can be built within a few hours and only requires between (200 MB and 2GB) of 
data" (Interviewee 1). 
The amount of data depends on the particular company-specific intension and statistical model. 
While time-series scrutinizes, require only a few data, text and picture analyses call for more 
eloquent data in order to achieve a beneficial outcome. In that sense, pharma's need to raise the 
question of whether they have the resources to deal with these issues or alternatively outsource 




4.2.4 Predictions and forecasts as the leading functions of ML  
ML learning-enabled applications will significantly change the pharma’s performance and 
workflow. Forecasts report that in the next 15-20 years, 50% of the jobs will shift towards 
automatization (Interviewee 1). Form a business point of view ML- applications leading to 
shrinking labour costs (10 robots can replace 100 employees), flawless compliance and risk 
management (contract, invoice checks), higher productivity (24/7) and efficiency (4-5 time 
faster) and thus, generating new revenue streams for the company (McKinsey, 2018). 
Recalling the most common ML applications from chapter 2.1.4 the interviewees evaluated 












































Success Factors of ML applications in % based on the 
Intervieews agreement
Success Factors
Figure 13: Success factors of ML applications (own representation, 2019). 
Table 4: Overview of the most useful ML applications/ functions by ML-experts (own representation, 2019). 
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accompanied by RPA & text and image recognition with 66, 6% each and robots & bots with 
33, 3%. 
Despite the four applications, interviewees did not mention further applications. Insofar it can 
be assumed that this is the central application backed by ML algorithms. The sales process 
consists of different phases and complex activities. Hence the upcoming question is where to 
implement the applications within the sales process of pharma's to reach an efficiency increase. 
The interviewees highlighted the following intersection where ML applications and functions 
can remit an unusually high degree of value (interviewee 1, 2, 3, 4, 5):   
1)    … everywhere where data points exist, 
2)    … everywhere where time-consuming and monotonous tasks exist,  
3)    … everywhere where repetitive, less complex tasks exist, 
4)    … sensors or other tools collecting data and transform these data into numbers, 
5)    … data are stored and analysed, 
6)    … standardized models and software systems implemented. 
Given the fact that sales activities be allocated to repetitiveness and complexity mentioned 
above, the following section will derive a model classifying the sales tasks with the highest 
potential to increase the efficiency of the unit.   
4.2.5 Low hanging fruits can be identified in different sales phases 
The sales process, as a data-driven operation, gathers many data creating massive databases and 
thus accomplishes solid ML-prerequisites (Interviewee 1). Statistical data can be compared in 
any step of the sales process enabling ML-functions e.g., predictions to support the operations. 
Acknowledged by the literature and proofed by ML experts, less complex, repetitive and time-
consuming tasks are the low hanging fruits for companies striving for sales efficiency 
improvements (see chapter 4.2.4). The following metric (figure 14) provides an overview of 
the accumulated sales tasks stated in the interviews and the academic literature. The metric 
consists of two axes that organizing the sales actions regarding their level of complexity and 
their repetitiveness. These attributes intend to recognize the sales tasks with the highest ML-
potential to maximize the effectivity and efficiency within the sales department. Thereby, the 
horizontal axis displays the repetitiveness of tasks. The more often an activity is executed, the 
higher is its monotony-degree as well as time-exposure among employees. Thus, their 
replacement potential through ML applications is the highest. The vertical axis illustrates the 
level of complexity. More complicated duties require more data, specific know-how, more in-
depth analyses, as well as interconnections. That is why the development of particular ML 
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algorithms and analytics is more difficult for more complex tasks. By integrating the two 
dimensions, the activities can be assigned to four distinct groups. 
Low Hanging Fruits (Lhf) can be defined as activities that are highly repetitive (mostly on a 
daily basis) and less complex (few data necessary, easily structured). Thus, they might be 
realized quickly within the business unit. Often these tasks are monotonous and time-
consuming (interviewee 9).  Therefore they have a high potential in increasing sales efficiency 
rates. Examples are the entire data management category (see chapter 4.1.3) as well as e.g., 
document checks regarding compliance and risk as well as different kinds of trends or market 
analyses. The second category is "2nd priority tasks," which are tasks that are more likely 
executed weekly than daily. They ask for more data inputs, and their correlations with other 
units/topics are moderately complex. Thus, the effort to support these activities by ML-
applications is higher than Lhf tasks. Examples are product demos and the development of 
presentations for the latter ones.  
3rd priority activities characterized by their high level of complexity and carried out on a 
monthly base rather than on a weekly base. They have more intersections within the decision-
making process, frequently need human abilities and more data. Examples might be 
renegotiations or the first draw of proposals/ contracts. Tasks that are only performed once per 
quarter/ year are not captured in the metric because implementation costs would exceed the 
efficiency ratio undoubtedly. 
On the contrary, companies fostering efficiency within their sales unit through ML applications 
should focus on the beginning of Lhf because they are more straightforward to realize and faster 
to accomplish. More complex tasks expect better data knowledge, analytical understanding, 
time integration effort, and more extended training of the algorithm. Because the 




Figure 14: Classification of sales activities according to repetitiveness and complexity (own representation, 2019). 
Given the result that some activities are extraordinarily time-consuming, these tasks are 
designated by high ML potential. That is why, in the following step, a "time" dimension will 
be appended to the model (figure 15). These tasks are impeding sales inputs (calls, demos etc.) 
and thus the overall efficiency and effectiveness. Besides, these tasks are immense cost factors 
within pharma's and concurrently impeding salesforces from focusing on their core activities of 
forming new customer relationships.  Hence, the new model (determines) determines highly 
time-sensitive activities. 
 
Figure 15: Classification of sales activities according to an additional time dimensions (own representation, 2019). 
Time savings in sales departments allow the salesforce to centre on more on value-generating 
tasks e.g., customer service, identifying cross- and upselling potentials. The categorization 
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reveals that especially data management activities are time-consuming because they are not 
automated. In case these tasks are not automated, it is challenging to commence integrating 
ML-applications.  
4.2.6 RPA has a high potential to enhance various sales activities  
The analyses from chapter 4.1 and 4.2 pinpointed LHF as the most significant enabler of ML-
applications. In the second step, duties which are time-consuming and therefore unbeneficial 
from the business perspective were highlighted. The subsequent table 5 will display the 
elaborated activities and match them with the four specific ML applications and functions, 
recalled from the interviews and the literature review.  
The table reveals that within the sales department, RPA has the potential to overtake the 
majority of the tasks. New software systems like Blue Prism, Automation anywhere or UiPath 
record core-process and automate the latter one based on ML-algorithms. Thus, processes can 
run on a higher quality saving time e.g., for the entire data management and integration process 
(Interviewee 5). Real-time data allow pharma's to set the right priorities i.e., spend the most 
time on the most relevant customers. During sales calls, apps and mobile devices enable the 
staff to access the entire product portfolio directly. They can interactively configure offers and 
include relevant customer data. Availabilities and delivery terms can already be clarified during 




Table 5: Overview of sales tasks matching particular ML applications/ functions (own representation, 2019). 
Through NLP, psychological behaviour might be analysed (lexis and word melody) and thus, 
the application could advise the salesforce in real-time by figuring out the semantically related 
texts and its purpose behind. Thus, customer interaction and buying triggers can be identified. 
Hence, the entire customer interaction can be tracked and recorded automatically, avoiding 
manual input in the system, which saves time. Furthermore, the risk of suffering significant 
information about the client will be mitigated. NLP also enhances the error susceptibility when 
creating or proofing invoices and contracts (Interviewee 3). Especially in fast-changing 
environments as the pharma's, new regulations and compliance restrictions might be 
automatically checked and drawn up. Besides, the proposal and client needs are natural 
matchable and adaptable.   
Predictions and Forecasting  
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Precise predictions and forecasts save hidden costs as well as resources and thus could facilitate 
to determine pharma's sales goal correctly. Especially, deep learning approaches are 
outstanding in classifying patterns which humans would not discover. Thus, clear and accurate 
outputs of a prediction either as future forecast numbers or the probability of a status quo might 
be derived supporting the sales rep on a daily base (Interviewee 1). Since ML-applications can 
"learn" organizations can train the algorithms on consumer behaviour, thus predicting its 
customer behaviour/ habits resulting in the right demand forecast. Moreover, services and 
products can be served with the right advertisement and buying triggers, e.g., the best timing, 
prices, or discounts are predictable. Through optimal changes in variables, the accuracy of the 
forecast can be maximized.  
Robots/ Bots 
The most current technology based on ML might be chat- and other software bots. These bots 
can ensure a 24/7 customer service 365 days a year, without the risk of being sick or the demand 
for holidays. Nevertheless, a full replacement of sales reps in pharma's is impossible due to the 
weight of personal contact. Still, bots can ensure simplified and fast feedback from the client. 
Mostly this technology is enabled by an RPA software (Interviewee 5)  
As illustrated in table 5 ML-application can be integrated throughout the entire sales 
department. The question is how efficient and effective are these implementations from a 
business point of view. Thus the next section will analyse the most efficient and practical 
applications for the sales department.  
4.2.7 ML technologies foster an efficient sales process  
The following model (see appendix) illustrates the final model. In the previous step, the 
activities of the salesforce were matched with the compliant ML-function/ application. This 
model adds a more fabulous description to the respective intersection between sales activity 
and ML-technology. Afterward, the described action is evaluated in terms of efficiency criteria 
which are based on the chapter.2.4.1 determined as: 
1)   Time reduction potential 
2)   Cost-saving potential  
3)   Quality enhancement 
4)   Risk and loss mitigation 
In chapter 2.4.1, efficiency was defined as an input-output ratio. This ration can be enhanced 
by decreasing time and costs for activities, leading enable the salesforce to focus on their core 
activities. Effectivity was related to the overall sales volume. To boost sales, the company ought 
 
 46 
to sell the best quality product. Through ML-enabled technology, high-quality information 
standards are ensured. Through fast and secured control mechanisms, the transactions can be 
handled much more quickly, leading to long-lasting relationships with B2B customers from 
pharma's.    
According to the number of anticipated evaluation criteria (1-4), each activity-tech-pair 
ascertains an estimate between 0 and 1. These values are between 0 and 1. 1, determines the 
most efficient/ effective value (table 5). That implies that the assigned ML technology has a 
very significant impact on sales activity efficiency/ effectiveness. Proceeding, 0 goes along with 
the assumption that ML technologies cannot support the particular task. These activities are 
excluded from the following calculations of the ratios. The overall objective of the index is to 
distinguish tasks that can maximize the efficiency of the sales process through ML-applications/ 
functions.    
In general, all of the four identified ML technologies have the potential to increase the sales 
input ratio in pharma's (figure 16). Even though RPA has the most intersections with several 
sales activities, it is less efficient/ effective in its usage (0, 72). Surprisingly, NLP (0, 78) as 
well as predictions (0, 78) are the most efficient/ effective ML-applications followed by robots 
and bots (0, 75).  
It is explainable by the impact of the phases on the external as well as internal operations. 
Within both phases NLP and predictions have the potential to foster accuracy, speed while 
simultaneously decreasing costs for processes in terms of employee cots. Chat-/ or service bots, 
for example, significantly intensify the whole customer journey and internal operations on a 
large scale by increasing reaction times. RPA (figure 17) has a lower efficiency because it can 
be applicable to more sales task than the other technologies (18). Thus, RPA also optimizes 
Table 6: Evaluation scale for ML applicable tasks (own representation, 2019). 
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supportive tasks which add less value to the process optimization and thus the efficiency 
average ratio is smaller. 
 Figure 18 reveals that the implementation of ML-technology within the closing phase (0, 96) 
resembles to have the most powerful potential to enhance the effectivity and efficiency of the 
sales process. Related to the fact that this phase includes much administrative work as 
contract checks, invoice generation, and adaptions, the high potential appears reasonable. 
Most likely, NLP software can save much time throughout the whole stage. In total 
compliance with previous insights, after-sales applications (0, 94) can facilitate the entire 
customer service and information, attainability, and information quality of the customer 
Figure 16: Average of the overall efficiency/ effectivity ratio of ML technologies throughout all sales tasks (own 
representation, 2019). 
Figure 17: Number of sales tasks matched with the particular ML technology (own representation, 2019). 
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service. Relationship management (0, 88) characterized by much time consuming repetitive 
work, takes the 3rd position in the ranking. Surprisingly, data management tasks (0, 66) take 
together with the offering phase (0, 59) the worst ranking. Although data management tasks 
are Lhf, the results gained show less influence on efficiency and effectivity value. The reason 
for this somewhat contradictory result can be the fact that these tasks do not have directly 
apparent customer value. They more likely impacting the sales operations and passively 
fostering sales itself. The lead and planning phase consists of various analyses, accounting for 
0, 67. The calculation of the efficiency/ effectivity ratio on a task basis (horizontal) 
corresponds with  the previous analysis because the closing phase contributes 50% to the most 
efficient sales activities, namely proposal matching (1,00), invoice and contract management 
(1,00) as well as final contract check and sign off (1,00) (figure 19). 
While 1, 00 determines tasks where ML-applications can enhance the process effectivity and 
efficiency significantly, activity value 0, 5 is also positively influenced by the implementation 
of ML applications. Moreover, the activities which directly target the customer seem to have a 
higher efficiency/ effectivity increase than internal tasks e.g., sales forecasts and data 
tracking. 
  





4.2.8 Managerial Implications to maximize the value within pharma’s sales department 
The conducted research validates the hypothesis that ML applications can significantly enhance 
sales operations within pharma's. In times of fast-changing environments, data-based business 
insights and predictions, as well as real-time data, are essential success factors for pharma's. 
ML-applications within the sales department can relieve the salesforce, even to overachieve 
determined goals. In order to implement ML application within the sales department in 
pharma's efficiently for the future, three steps are essential. 
Set up a solid base for the development of ML applications  
The starting to maximize ML applications is a profound base. That implies the commitment of 
the board of the pharma's. The management must understand the value of new technology and 
integrates the strategy into the corporate culture. This will facilitate communication within the 
company and ensures the acceptance rate of the employees. Besides, a solid IT-infrastructure 
and security base must be established in order to guarantee smooth data flows within the 
company. In the next step, critical operations and activities need to be pointed out. Excellent 
guidance for that is BPM software like Kissflow or ProcessMaker. When processes, as well as 
activities, are transparent, “red flags” are effortlessly recognizable. 
Implement a successful ML-strategy in the sales department  
As soon as the company decides to implement ML technology within their business unit 
employees need to be involved and trained during the entire implementation process. Solely 
Figure 19: The impact of ML applications on the efficiency/effectivity of sales tasks (own representation, 2019). 
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reliable communication will prevent the pharma's from misconceptions across the salesforce. 
A good understanding of technology leads to more efficient utilization prepares the salesforce 
for the change. That is why it is likewise crucial to accelerate small steps of change. Thus, 
employees can test the new applications from the beginning and integrate them slightly to their 
daily routines.  
Evidently, the emphasis is on the identification of the most efficient tasks acknowledging the 
implementation of ML applications. First, starting with the classification of repetitive, time-
consuming, and less complex activities is essential to discover Lhf, which bother the majority 
of the employees in sales. Secondly, a match of the particular task with the appropriate 
application requires a good understanding of the issue. Within sales departments in pharma's, 
the study examines the closing and after-sales phase as the first touchpoint of efficient ML 
integrations. More precisely, invoice- and billing documents through RPA and software bots, 
contract checks/adjustments through NLP and customer service through Chabot’s/ RPA are the 
most solutions maximizing sales department efficiency.  
Constant enhancements and improvements  
After a flourishing implementation of an ML solution, it is crucial to encourage the exchange 
between the sales department and the developers. The exchange fosters the accuracy of the 
algorithm for particular pains. Thus efficiency ratios within sales can be ensured, and pharma's 
reach their sharp objects.  
If the three steps are integrated into the corporate culture, ML can assist every department to 





5 CHAPTER V: RESULTS  
The purpose of this research study is to assess the possibility of ML applications and functions 
within the B2B sales process for pharma's. The underlying research constitutes results with ML 
experts, sales representatives, as well as consultants interested in the topic. In line with the 
results of Wenzel, 2014, pharma's are strongly depended on continually changing regulations, 
new restrictions, and price pressure. Pharma's are aware of these challenges and try to find new 
ways to gain competitive advantages.  Most likely process optimization is the cheapest and 
most effective way to reduce operational costs, simultaneously improving customer 
satisfaction. Enrichments in terms of speed and accuracy, advanced risk management, and the 
mitigation of compliance risks are only a few approaches to foster the overall companies’ 
performance. On the other hand-side, pharma's predetermine ambitious sales goals for their 
salesforce, who are often under enormous time and pressure. The results of the conducted 
interviews assess the four main applications/ functions, namely RPA, predictions, NLP, and 
robots which go along with the assumptions from Burgess 2017. By evaluating these 
technologies, the underlying study emphasizes that the benefit of these applications is to 
maintain and replenish time-consuming, complex, and repetitive tasks. The characteristics seem 
a great fit to support the salesforce within pharma's by facilitating their work. Thus, sales reps 
can focus on their primary objective of building up client relationships. 
Further investigations revealed that ML potentials within the B2B sales process in pharma's are 
given but unexploited to a large extent yet. To overcome the obstacles and foster ML 
applications within the sales department, pharma's ought to create a joint base. Education of the 
sales representatives, integration of ML-applications into the corporate culture, but also set up 
the right prerequisites as an efficient IT-architecture/ IT security system in order to prepare the 
salesforce for changes and innovations, are essential to increase the sales department’s 
processes.   
The present study also gained insights into the possible connection between ML applications 
and respective sales tasks. Thus, Lhf as data management tasks, billing, and invoice and contact 
management, customer service is a beneficial opening point for pharma's ML journey.  By 
matching the tasks with the particular ML application function, an overall overview indicates 
which appropriate technology can optimize the particular task. By evaluating the efficiency and 
effectivity potential of the ML-technologies, the NLP and predictions can maximize the sales 
process efficiency in pharma's best. By evaluating particular activities, direct customer-related 
tasks like enriched customer service, contract- and invoice checks, feedbacks, as well as 
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billings, have the highest value to maximize the sales department's outcome in terms of 
efficiency increase for the future. 
 
6 CHAPTER VI: LIMITATIONS AND IMPLICATIONS FOR FUTURE 
RESEARCH 
As with all empirical studies, the underlying analyses come with several limitations. First, due 
to the limited time frame, the sample size of interviewees from pharma’s salesforces is too small 
in order to generalize the entire sales process, including all activities. Sales representatives are 
reserved for proclaiming information about technologies and internal processes. Moreover, the 
entire industry seems restricted to external research. Thus, for further investigations, more 
industry experts should be interviewed. Second, due to the research design, described as semi-
structured-interviews, the results are likely to suffer from a large scope for interpretation. 
However, the method was proficient at levying results about state-of-the-art ML applications 
and an overview of the general B2B sales process in pharma’s. The conducted research 
identified Lhf fruits and matched particular activities with one or more fitting ML applications. 
Although these technologies and tasks measured in terms of their effectivity and efficiency, it 
is undefined how long and at which costs the businesses can integrate the presented solution. 
Even though this reassessment can change the efficiency/ effectivity rate of the respective 
solution, the ratio indicators are determined based on assumptions from the interviewees and 
the literature review. An alternative valuation can change results significantly. The same applies 
to the evaluation of the sales activity categorization in chapter 4.2.5.  The underlying thesis 
assesses that ML-applications can maximize sales process operations. 
On the contrary, it is impossible to predict the future potential of ML, based on Moore’s law, 
“If something cannot go forever, it will not” (Zhou. 2017). Therefore, further investigations of 
ML algorithm limits would be an exciting objective for further researches.  
The research contains solely western literature. Including Chinese literature (leading country in 
AI based technologies) would presumably gather more in-depth insights into ML technologies. 
Thus, more than four ML functions/ applications could be recognized. Nevertheless, the scope 
of the study does not permit to evaluate more than the four Ml technologies.  
A critical success factor in maximizing the sales service through ML applications is to educate 
the employees about new technological innovations and changes. That is why new units 
(intermedia’s) or roles need to be established. These roles can foster the exchange between the 
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IT department and sales in order to exchange information and thus foster the whole business 
outcome. The job-description of such an intermedia can be an exciting future research topic. 
 
In summary, the underlying research contributes to the academic ML literature by examining 
unexplored ML potentials within sales processes in pharma’s. In the next years, ML 
applications will be integrated into various new units and processes within pharma’s. Thus, 
further researches will proof whether ML can be a long-term game-changer for efficiency and 
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8.1 Appendix 1: Interview Guide 
Target Group I: ML Experts 
 
The Impact of Machine Learning on the efficiency of the B2B Sales Service in 
Pharmaceutical Companies 
 
RQ: How can Machine Learning-enabled tech/functions maximize the efficiency of the B2B 
Sales Service for Pharmaceutical Companies in future? 
 




1. Please introduce yourself briefly and describe your position within your company/ 
university/ field of research. 
 
 
Nowadays, the competitive advantage of companies is often based on technological progress. 
Especially, the impact of new technologies like AI/ML and their implementation within 
company’s value chain increased significantly and might influence the future business 
operations even more [Capo et al. 2014]. 
 
2. Do you think the rise and importance of AI/ ML will continue to grow or do you think 
the technological limitation has risen? Why do you think so? 
 
3. What do you think are the key challenges for the future development of ML? 
 
 
ML’s has various capabilities like speech & image recognition or prediction. Hence, these 
capabilities enable different technologies, i.e. Chabot’s, or functions, i.e. robotic process 
automatization [Burgess. 2017]. 
 
4. In your point of view, what are the main capabilities of ML and which technologies 
and functions may be enabled by these capabilities in the future? 
 
 
Within pharmaceutical companies ML is often used for pattern discovery which can be used 
for drug discovery and precision medicine applications and process optimization, i.e. 
customer analysis, leading to cost reductions and enhancing profitability in a high 
competitive industry [Cui et al. 2006; Burgess. 2017]. 
 
5. In which business units (R&D/ marketing/sales/supply chain etc.) of a 





6. What do you think are the main challenges for implementing ML algorithms in 




Sales forces are main drivers of company profitability aiming for customer attention, 
retention and satisfaction. That is why sales mangers strive for permanent process 
optimization and efficiency within their departments [Zolter et al. 2009; Shi et al. 2017]. 
 
7. Where do you identify the biggest potentials for ML in the sales process and what do 
you think which tasks could be supported in the future sales process through ML? 
 
8. Do you think that a full automatized sales process is realistic and could fully replace 
humans? 
 
9. Where do you see machine learning in 5 years/ 10 years? 
 
Target Group II: Sales Experts (Pharma) 
 
The Impact of Machine Learning on the efficiency of the B2B Sales Service in 
Pharmaceutical Companies 
 
RQ: How can Machine Learning-enabled tech/functions maximize the efficiency of the B2B 
Sales Service for Pharmaceutical Companies in future? 
 
 




1. Please introduce yourself briefly and describe your position within your company 
 
2. What’s your company’s position in the pharmaceutical industry and how would you 
describe your company in terms of type; dimension (employees) and market (markets 
your company is targeting)? 
 
 
Mainly, the pharmaceutical industry may be characterized by risky and long R&D processes, 
a high competitive market for intellectual property, threats of substitutes, restrictive legal 
regulations and strong sales- & purchase pressures [Bátiz-Lazo and Holland, 2001]. 
 
3. What are the biggest challenges for your company at the moment? 
 
Sales force performance can be measured in terms of monthly sales, up- and cross-selling 
activities and subsequently, monthly sales growth/ closing ratio [Ramarajan et al. 2017]. 
 
 





5. Which different sales types (inside/outside sale, client services, lead generation etc.) 
exist within your company and who are they targeting? 
 
 
Traditionally, the sales process within companies consists of seven different steps. (1) 
Prospecting, (2) pre-approach, (3) approach, (4) presentation, (5) overcoming objections, (6) 
close, (7) follow up/post scale activities [Moore et al. 2015]. 
 
6. What are the typical steps of the B2B sales process within your company? 
 
 
7. Given your opinion what are the typical tasks in your B2B sales department? Are they 
classified (e.g. repetitive vs non-repetitive tasks/standardized vs. non-standardized 
tasks/daily vs. weekly vs monthly tasks)? Are there any tasks outsourced? 
 
 8. What are the biggest challenges of the internal B2B sales process? 
 
 
Nowadays, the competitive advantage of companies is often based on technological progress. 
Especially, the impact of new technologies like AI/ML and their implementation within 
company’s value chain increased significantly and might influence the future business 
operations even more [Capo et al. 2014]. 
 
9. In what level, technology is already integrated within the sales process in order to 
support the mentioned tasks and challenges? Are there technological incentives within 
your company to foster technology? 
 
10. What are the lessons learned from the implementation of a new technology? 
 
 
ML’s has various capabilities like speech & image recognition or prediction. Hence, these 
capabilities enable different technologies, e.g. Chabot’s, or functions, i.e. robotic process 
automatization [Burgess. 2017]. 
 
11. Are there any AI/ ML applications already implemented in the current sales process? 
 
12. What do you think at which touchpoints ML could support your daily work? 
8.2 Appendix 2: Interview Guideline 
The Impact of Machine Learning on the efficiency of the B2B Sales Service in 
Pharmaceutical Companies 
 
RQ: How can Machine Learning-enabled tech/functions maximize the efficiency of the B2B 
Sales Service for Pharmaceutical Companies in future? 
 
Interviewer: Mr. Tobias Brengel       Date: 15.04.2019 




1. Please introduce yourself briefly and describe your position within your company/ 
university/ field of research. 
Interviewee 1 has a technological background and is a data scientist and AI expert who consults 
firms in order to implement AI/ ML functions and application within their business processes. 
He is specialized in deep learning a neural networks. 
2. Do you think the rise and importance of AI/ ML will continue to grow or do you think 
the technological limitation has risen? Why do you think so? 
As long as you can transform your data into numbers/series of numbers ML can be implemented 
everywhere. That is the case for all the data currently existing. 
3. What do you think are the key challenges for the future development of ML? 
Legal restriction to make data digital. E.g. in Russia there are e-health companies collecting the 
data and the data are gathered and used from an IT-instance centrally (data protection policy 
not too strict). The Russians can forecasts in that sense how a virus processes in course of the 
times and also predict epidemics. So the system could recommend you to not enroll your child 
in school because the probability is by 95% given that the particular virus will occur in school. 
Neural networks are an algorithm from ML and a lot of data are required. Other algorithms 
don't need that many data. But algorithms which are no neural networks are less scalable in 
terms of samples, while a neural network can also work with big data but it is not necessary. 
E.g. for time series analysis you don't need a lot of data (200MB-2GB) while you need for text 
and picture analysis which are more complex a way more data are required. When it comes to 
set up a neural network/ ML algorithm you use 20% of the time to analyze and code/ build up 
the problem, the other 80% are classical data science work like gather data, iron out data, 
balance data, code data (human based) and train. If data not clean, you don't have the right 
amount of data (doesn't have to be that much) you’re not coming that far and struggle. A 
prototype can be built within a few hours. 
Often, solutions are available but from process perspectives view in big cooperation’s you need 
people who are free and can deal with that subject in concerns. Often, these people don't have 
time and decisions take long that is why as a startup it's a way faster. The information and 
clarification within a department is essential for the success of the implementation of new 
technology, but most of the people think Big Data/ ML is a huge sorcery and thus missing the 
chance of implement. 
4. In your point of view, what are the main capabilities of ML and which technologies and 
functions may be enabled by these capabilities in the future? 
Prediction and Forecasting. Automatization. 
DEEP LEARNING AND neural networks overcode the classical machine learning algorithms 
especially in text processing, image recognition and time series analysis. Deep learning 
approaches are very good in discover pattern in datasets and then you can do two things: 1) 
classify pattern (categorize) or 2) carry the pattern forward (regression, time series analysis) 
prediction. Always when you insert number and you get an output it is kind of a prediction 
either it can be a future forecast number or the probability of a status quo. Focal point is that 
humans cannot see the particular pattern which is the machine able to discover. For the human 
it is chaos for the neural network it is a nice pattern. 
5. In which business units (R&D/ marketing/sales/supply chain etc.) of a (pharmaceutical) 
company would you see highest potentials for ML applications in the future? 
Definitely we have to be aware of the fact that within a company there are a way more use cases 
available in every department. 
6. What do you think are the main challenges for implementing ML algorithms in a 




Requirements for a successful implementation of ML is that you need to anticipate that there is 
a pattern in data e.g. weather data (daily/yearly fluctuations). 
The success factor is to train and optimize the dataset and try very different variable 
combinations. E.g. in winter time there is a higher probability of influenza than in summer, 
because the temperature goes down and thus, you can increase the production. So in case you 
have enough data it is possible to make a precise forecast. 
Another success factor is that it is quiet easy is to convey the different layers (with number 
inputs transformed into number output) of the algorithm from one domain to all other domains 
like time series, natural language, text, pictures, 3D-models, behaviors and videos. The only 
question is which data are available and which problems are in the dataset. 
When it comes to analysis e.g. time series analysis it is better to have data gathered over von 
cycle (year) in order to come up with reasonable results, because of the velocity. 
Neural networks solve the same problems as ML but with a higher degree of accuracy. That is 
why it is also good to implement. 
7. Where do you identify the biggest potentials for ML in the sales process and what do 
you think which tasks could be supported in the future sales process through ML? 
Sales is an area with a lot of data and huge databases. That is why it is possible to use ML in 
almost all steps of the sales process. One use case is to predict the likelihood of events and 
through the change in variables you can maximize the likelihood of buying a product, sales 
forecast (train set). Bots which support the sales representative which advices in different cases 
the salesforce. Neural networks which can analysis the written text in terms of embedding the 
written text semantically, figure out how semantic related texts are, what the feeling behind 
words is. On the other hand-side ML can support psychological behaviors e.g. analyzing the 
voice (word melody etc.). Whenever you have sales interviews with the clients in some cases 
an AI algorithm listen to what you say and give the salesforce real time advices. 
In sales we have two different data sources. On the one hand-side we have mere data from the 
sales database e.g. CRM (flu vaccination winter). 
Recommendations and advertisement which is personalized on your own interest and needs. 
What is means is that you can train the neural network on the consumer behavior of the customer 
resulting that you can predict the behavior of the clients and in accordance with that serve the 
right ads or buying triggers. The consumer behavior can be analyzed with a high accurate 
probability because our habits are pattern which can be displayed mathematically. So in case 
you have a lot of data over a specific time period, neural networks can be created easily. 
8. Do you think that a full automatized sales process is realistic and could fully replace 
humans? 
Definitely. There is an international competition for drug discovery (protein-complexes). There 
was a community of 20.000 people and there were some people from Deep Mind and they made 
a used case out of it and won the protein competition. They were better than the community. 
9. Where do you see machine learning in 5 years/ 10 years? 
There are forecasts that in the next 15-20 years 50% of the jobs will shift based on 
automatization. That does not mean that 50% got unemployed but the jobs will shift. E.g. no 
taxi-drivers when we have autonomous driving. In company’s there will be a shift as well 
meaning that repetitive and followed pattern tasks could be fully replaced. In the next time it 
will start that sales people are support by new tools in order to make better sales predictions to 
optimize sales. Sales robots will be a future step though in order to cancel out the salesforce. 
AI on the current step cannot be creative by itself. It can interpolate but extrapolate! It can react 
on known pattern (maybe also empathic) but that's more human-machine interaction! Facing 
can be seen as a solution at current stage. 
Interview Summary 1: 
 
 M 
Interview partner A is a data scientist and AI expert who consults firms in order to implement 
AI/ ML functions and application within their business processes. He is specialized in deep 
learning and neural networks and a leading consultant when it comes to the implementation of 
ML solutions. He proclaims that the ML potential is immense and solutions can be implemented 
everywhere where you can transform your data into numbers/series of numbers. That is the case 
for all the data currently existing. Moreover, ML applications can be integrated within every 
part of the entire value chain within pharma’s He highlights neural networks and deep learning 
algorithms as the real game-changer for future machine learning applications because they can 
classify and moving the pattern forward leading to a more precise results. That is one of the 
reason why he mentioned predictions, forecasts as well as automation as the core technologies 
supported by ML algorithms. He lays out that the implementation of such a ML algorithm 
within the business unit is simple and not really costly which is another competitive advantage 
of the technology. Moreover, he criticizes the process perspective in big firms and highlights 
the importance of people who can deal with the technology as well as the understanding of the 
particular business unit. That is why he relates to startups which can develop such solutions a 
way quicker. He evaluates the sales department in pharma’s as a good field of implementation 
based on the huge amount of data which are generated on each step of the customer journey. 
The scope of implementation goes from advertisements, over Chabot’s to the usage of neural 
networks to identify hidden pattern in the data. In that sense he mentioned data quality and 
constant inputs as the main success factors for a successful data management flow within the 
business unit.  
He also assumes that the entire sales department can be automated and replaced at one point 
and mentioned protein competitions were the deep mind algorithms outperformed human 
beings.  
He evaluates ML as future game changer for business optimization but also agrees on the fact 
that the outcome and the real value of machine learning applications cannot be measured at this 
point of time.  
He ensures that job descriptions and job tasks will significantly change within the next 20 years. 
Thus, new tasks which are related to the control of the machines will appear. 
 
The Impact of Machine Learning on the efficiency of the B2B Sales Service in 
Pharmaceutical Companies 
 
RQ: How can Machine Learning-enabled tech/functions maximize the efficiency of the B2B 
Sales Service for Pharmaceutical Companies in future? 
 
Interviewer: Mr. Tobias Brengel       Date: 24.04.2019 
Interviewee: Interviewee 2 
 
1. Please introduce yourself briefly and describe your position within your company/ 
university/ field of research. 
Interviewee 2, is an assistant professor in the information systems department at Catholica 
Lisbon. He is trying to understand the economics of AI. One of the project is to understand the 
race between humans and machine. The setting within is a large new organization that replace 
human editor who is doing the ranking on the front page of newspapers articles with a 
recommendation engine. It's a field experiment so some users randomly get assigned to getting 
the recommendation and others see what the human has selected for them and we then try to 
understand under which situations the machine can outperform the human in terms of clicks. 
The most interesting finding is in order to outperform human the machine needs data, but more 
 
 N 
data is does not necessarily always better but there are some decreasing returns to data. So at 
one point the curve simply flats out. 
2. Do you think the rise and importance of AI/ ML will continue to grow or do you think 
the technological limitation has risen? Why do you think so? 
Now the technology is good at specific domains, recognizing objects, animals and stuff and 
pictures better than humans, in other things it’s not so clear too little data the human is better to 
pick news articles that you like and once it knows more about your preferences the machine 
outperform the human. There are two things: 1 is the context specific sort of limitation and the 
other is the data limitation on both ends (not only too much but also too little data) doesn't help.  
3. What do you think are the key challenges for the future development of ML? 
If you define AI as a machine that has some general intelligence doing more than e.g. excel and 
one specific area, then trying to see how you can combine all the individual domain specific 
excellences into one system that would be the big challenge for the next years. But do we want 
that because basic economic theory also states that specialization is good and everyone benefits 
from specialization, so it’s not sure you want to invest in something that is general. Probably 
you won’t be able to come up with something that is an expert with everything, so again you 
have the trade-off between generalist and specialist.  
4. In your point of view, what are the main capabilities of ML and which technologies and 
functions may be enabled by these capabilities in the future? 
Prediction is the key skill that the machines have because in the end it's a fancy statistical model 
using data to make sense of historical data and then try to predict into the future. Every task 
which involves a kind of prediction will be one where you can use a machine. It’s just a matter 
of how you get access to data. Maybe for some things new sensors have to be developed or 
creative grace has to be developed on how to use existing sensors, because the types of data 
that are in the real world exist so many different kind of data. Now we are used to think about 
data in terms of spreadsheet s and numbers, but also picture/pixel recognition (also transformed 
in numbers and spreadsheets). When you think about other prediction tasks we might come up 
with some new sensors which transform and capture data into numbers and spreadsheets.   
Almost everything is basically enabled by prediction so e.g. self-driving cars predict all the 
objects on the picture, and applications like demand forecasting. There is a lot of work in trying 
to come up with applications and predictions, so if I would have a brilliant idea I would probably 
not sit here. Automation based on robots and when it comes to B2B market it would probably 
more interesting in logistics like self-driving trucks, self-loading trucks. If it’s more in B2C 
market there is some scope for replacing humans e.g. people who work on the vending 
machines.  
5. In which business units (R&D/ marketing/sales/supply chain etc.) of a (pharmaceutical) 
company would you see highest potentials for ML applications in the future? 
In the pharmaceutical sector you can have pharmacy’s which are open 24/7. And there could 
be a software part that understands what kind of medication you need and your doctor’s note is 
eligible. State of the art is that the usage of ML applications is more likely to be implemented 
in R&D as well as logistics department. The focus of ML is probably not on sales but 
somewhere else because the upside potential is larger because the R&D processes in pharma 
companies are highly uncertain and whatever you can do decreasing the cost of R&D is useful 
and probably sales is less a costs factor and therefore is less focus on trying to improve that. 
And there is also probably less scope to improve, because if you think about ML is good at 
prediction and trying to understand pattern, in the R&D processes/ research itself is looking 
basically on data and if you can structure it more it's a place where you can employ standardized 
models and software systems which tries to look for connections. In sales he doesn’t really see 
where the prediction part really comes, but of course you can make better prediction of who is 
going to buy what which comes back to the idea of demand forecasting and that's where people 
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and market research firms are already working on. In that way we would see ML only as another 
tool in the toolbox as a statistical tool.  
6. What do you think are the main challenges for implementing ML algorithms in 
accompany not using ML so far? What are the success factors of implementing efficient 
ML routines? 
It is important to understand how the models work and it’s not easy so I assume there is a huge 
change that you buy a black box software tool which is somewhere used in the firm but nobody 
understands what it is doing and where it makes mistakes and how large these mistakes are and 
so one the one hand-side do it internally is of course costly, and people understand the 
technology in the market are scares, but then buying it as package software solution makes sure 
you won’t be able to build up these capabilities within your firm. Ml is not only a software 
which defines the operations of the firm but its software which tries to change the operation of 
the firm and if you don't know exactly how it works at some point it can become a downside.  
7. Where do you identify the biggest potentials for ML in the sales process and what do 
you think which tasks could be supported in the future sales process through ML? 
The easiest short-run gains are looking at data which goes beyond the individual sales 
representatives to try to understand demand patterns or the willingness to pay of specific 
customers and then engage in optimizing on these domains, charging higher prices or discount 
rates. And sort of leverage on the experience or information an individual sales representative 
only uses for his/her own management of their work and sort of try to leverage on data of all 
your sales representative and try to find patterns and try to accumulate the expertise in some 
sense. Where machines are really good at is looking at larger amount of data and humans are 
limited in the intention, since we cannot look all the information which are out there, basically 
just looking at individual information some subsets or aggregates information. Answering 
emails and trigger customer’s decision can be trained on real time world data which is context 
specific and for examples which emails engaging in sales conversations it is easy to build a tool 
which answers to questions and emails.  
He currently read about data lake and I think the idea is that all data independent of its structure 
and format is somewhat connected and at the moment you pull it is being transformed into the 
structure you need for the specific model. So going from millions of emails coming in text files 
to transforming them into a spreadsheet which has front tools, subject, body, fields. 
8. Do you think that a full automatized sales process is realistic and could fully replace 
humans? 
That depends on the context, where you already find this is in stock trading. It is completely 
automated and this probably works because it is very standardized. Speed also matters because 
machines are good in doing things fast and doing things according to rules and 24/7. In other 
contexts there are much more benefit to social encounters, so the human part cannot be replaced, 
so something is not standardized, so you need somebody to explain or there are some other 
intangible things that cannot be really done by a machine. In the current state of art fully replace 
a sales process is not realistic but in case if the machine is very good in mimicking probably 
yes.  
9. Where do you see machine learning in 5 years/ 10 years? 
He has no idea! It is a black box. Within companies he really does not know because it is a lot 
of marketing and everybody is talking about that it is so important, but he guesses the people 
are talking about it are in the business of selling this technologies or selling services to 
implement this technology’s so for me it is not necessarily clear what the potentials are. In terms 
on research on technologies, we should head to predictions where we add causality. Now it’s 
just looking at pattern disregarding any causal mechanism, so that works fine if you want to 
detect cats on pictures because the way a cat looks won’t change. So you don't really need to 
understand why a certain formation of pixels in a certain area of a picture is correlated to being 
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a cat, but in other scenarios there is much more potential for the world to change and then this 
systems will fail if they don't have new data coming in all the time. Google search doesn't have 
to worry about causality because every time the word changes new data are coming in, and 
people have different search term and learn really quickly. But other things when you think 
you’re government and think about raise of lower taxes then you need to compare it to some 
counterfactual: what would happen if I raise taxes because you can’t simply raise taxes; even if 
you did then an evaluation of it afterwards could be confounded by so many other things that 
have changed in meantime. So trying to add this logic that people have thought about for a long 
time statistic to machine learning models will be the big step that will come and then it also 
opens up all kind of possibilities for all kinds of better prediction mechanism and make the 
prediction part better. 
Summary Interview 2 
Interviewee B, is an assistant professor in the information systems department at Catholica 
Lisbon and the ETH Zurich. He is interested in research and understanding how digitization 
affects firms, consumers and markets. And one aspect of this is trying to understand the 
economics of AI. However, he assumes that the success of ML applications is based on the 
access to data and the feed of the system. He thinks that AI as a machine that has some general 
intelligence doing more than e.g. excel and one specific area, then trying to see how you can 
combine all the individual domain specific excellences into one system which he determines as 
the big challenge for the next years. Moreover, he determines predictions in all different forms 
as the key skill of Machine Learning. He also mentions  automation based on robots and when 
it comes to B2B market and identifies intersections in logistics like self-driving trucks, self-
loading trucks. Moreover, he sees more in B2C market the potential to replacing humans e.g. 
people who work on the vending machines. Within pharma’s he says that ML is probably not 
on sales but somewhere else because the upside potential is larger because the R&D processes 
in pharma companies is highly uncertain and whatever you can do decreasing the cost of R&D 
is useful and probably sales is less a costs factor and therefore is less focus on trying to improve 
that. However, customer services can be significantly improved through the new technology.  
He describes the main challenge of the implementation ML enabled technology as a black box 
phenomenon which occurs in case the workforce which deals with the technology is not aware 
of its functions, features and outcomes. Moreover, he highlights the leverage on the experience 
or information of individual sales representative who can not only use the information for their 
own tasks but also try to leverage the data to find pattern and try to accumulate the expertise in 
some sense. Since specific knowledge is required, but also a solid IT-infrastructure businesses 
must deal with the question whether they would like to outsource the development of ML 
algorithm. His outlook is that ML applications will become more and more significant for the 
companies in future. This is one the one hand side due to the fact that there is a recent hype and 
a lot of advertisement around the topic, and one the other hand-side it can really increase 
performances on some scale. Moreover people will try to develop more and more precise 
insights into the algorithm and how to improve them. Thus, the result of ML applications in 
future will also be a black box. 
The Impact of Machine Learning on the efficiency of the B2B Sales Service in 
Pharmaceutical Companies 
 
RQ: How can Machine Learning-enabled tech/functions maximize the efficiency of the B2B 
Sales Service for Pharmaceutical Companies in future? 
 
Interviewer: Mr. Tobias Brengel       Date: 02.05.2019 




1. Please introduce yourself briefly and describe your position within your company/ 
university/ field of research. 
Interviewee C, is a post-doc researcher in the bio-engineering department at ETH Zurich. His 
PhD was in the Informatics department at Edinburgh University, and after that he did a post-
doc in the Engineering department also at Edinburgh.  
His research interests include image analysis (medical image analysis in particular), deep 
learning, representation learning, generative models and meta-heuristic optimization.  
2. Do you think the rise and importance of AI/ ML will continue to grow or do you think 
the technological limitation has risen? Why do you think so? 
He doesn’t think that machine learning methods have reached their limits, in the sense that 
people will continue to produce better and more broadly applicable algorithms for the 
foreseeable future. He also thinks that this question could be taken in several ways though:  
• Will AI/ML technology continue to improve?  Yes.   
• Will technology that already exists see increasing application? Also yes,  and 
this is also true even if research stagnates, there will still be a long  period of 
uptake of the technology.   
• Will AI/ML become more important? Well, I’m not totally sure what 
 important means I think there be more of it and it will it become fundamental 
to a larger number of companies.   
3. What do you think are the key challenges for the future development of ML? 
ML is a very broad field, and different sub areas will face somewhat different challenges. 
Herewith it could be data maintenance, and the adjustment of the right variables to the right 
algorithm. 
4. In your point of view, what are the main capabilities of ML and which technologies and 
functions may be enabled by these capabilities in the future? 
Currently the main strength of ML is its ability to automate tasks that would be otherwise time 
consuming and monotonous. Repetitive Task as well as task which require presence and time 
can be automated quickly. Deep learning potentials are another source for value generation 
because they identify pattern much faster. Moreover, they can identify pattern which are 
complex and not obvious for the human eye.  
5. In which business units (R&D/ marketing/sales/supply chain etc.) of a (pharmaceutical) 
company would you see highest potentials for ML applications in the future? 
Not really familiar with pharmaceutical companies but so it is hard to estimate where the highest 
potentials are right now.  Within a firms ML algorithm can undertake almost every task within 
the value chain. He sees the highest potential in the productions line. Predictions and automation 
can foster the efficiency of the entire process e.g. through predictive maintenance and RPA 
solution software enables product quality checks. 
6. What do you think are the main challenges for implementing ML algorithms in a 
company not using ML so far? What are the success factors of implementing efficient ML 
routines? 
One of the main problems is knowing what parts of your company’s operations machine 
learning might be able to automate. If you aren’t familiar with machine learning, and only have 
the abstract idea that machine learning is something that your company should be using, it isn’t 
really straight forward to know how to   
7. Where do you identify the biggest potentials for ML in the sales process and what do 
you think which tasks could be supported in the future sales process through ML? 
Uncertainties about the sales process. Customer Service might a good intersection for ML 
applications because they directly have a direct contacts to the customer, offering them an entire 
new customer journey.  
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8. Do you think that a full automatized sales process is realistic and could fully replace 
humans? 
He thinks the actual sales process is already essentially fully automated. It seems to me that 
what is currently less automated is for example the dispatch and delivery of the product after it 
has been bought. But certainly these things are already being worked on, with drone delivery 
and autonomous vehicles.   
9. Where do you see machine learning in 5 years/ 10 years? 
This is very difficult. He would think that where we are in 5 years might be also be quite 
different from where we are in 10.  
Summary Interviewee 3 
Interviewee 3, has a technical background and is a post-doc researcher in the bio-engineering 
department at ETH Zurich. His PhD was in the Informatics department at Edinburgh University, 
and after that he also accomplished a post-doc in the Engineering department also at Edinburgh.  
His research interests include image analysis (medical image analysis in particular), deep 
learning, representation learning. He assumes that the outcome of ML enabled technology and 
application is very hard to foresee because it depends on the human ability how they can adapt 
and change the algorithms based on their desired outcome. The challenge is right now to 
applicate ML algorithms to new business units and more broadly. Nevertheless, he assumes 
that the potential of ML is not reached yet and more and more applications can be enabled 
through the algorithms because. He highlights this period as the “period of uptake of the 
technology”.  From his point of view the two main applications of ML algorithms are RPA 
solution software as well as NLP solutions. Especially text and image recognition can enhance 
a lot of compliance tasks and automate checks and validations with an extremely low mistake 
rate. RPA solutions can guarantee time and costs savings when implemented on the right 
intersection. The biggest problem company’s struggle right now that they want to implement 
fancy ML solutions but either they do not have the compliant IT-infrastructure or the top-
management of the company misses out to integrate the ML-strategy within the corporate 
culture. If people aren’t familiar with machine learning, and only have the abstract idea that 
machine learning is something that your company should be using, it isn’t really straight 
forward. Thus, failures are preprogrammed. From his point of view ML integrations and the 
education of the employees is essential in order to feed the algorithm with the right data 
forecasting the anticipated outcome. 
He is not really familiar with the sales process and pharmaceutical company’s in general and 
can only think about customer services as the starting field of implementation. Moreover, he 
thinks the actual sales process is already essentially fully automated. It seems to him that what 
is currently less automated is for example the dispatch and delivery of the product after it has 
been bought. But certainly these things are already being worked on, with drone delivery and 
autonomous vehicles. In the future the confirms that the development and applications based 
on ML are quite different in 5 years from the ones which are going to be developed in 10 years, 
showing the huge potential of ML applications again. 
The Impact of Machine Learning on the efficiency of the B2B Sales Service in 
Pharmaceutical Companies 
 
RQ: How can Machine Learning-enabled tech/functions maximize the efficiency of the B2B 
Sales Service for Pharmaceutical Companies in future? 
 
Interviewer: Mr. Tobias Brengel       Date: 21.05.2019 




1. Please introduce yourself briefly and describe your position within your company/ 
university/ field of research. 
Interviewee 4 has a background in computer science. He worked in several startups as a 
software developer and also consulted business in terms of software strategies. He is now the 
head of Porsche digital, the new mobility and service hub of Porsche.   
2. Do you think the rise and importance of AI/ ML will continue to grow or do you think 
the technological limitation has risen? Why do you think so? 
The grow hasn't’ ended yet because ML’s implementation phase has only begun now. 
Publications in China and Germany are pretty strong in the field. In order to set up ML/AI to a 
new level completely new ways of thinking as well as ideas are necessary.  
3. What do you think are the key challenges for the future development of ML? 
• Nowadays, basic ML algorithms exists and there is no need to develop new algorithms 
because the real challenge is now to use these algorithms and adapt the use variables. In that 
sense the biggest challenge is to implement the modified algorithms within the company 
(ML-Implementation era), meaning within the existing systems, which also have to be 
aligned and adapted.  
• Most of the algorithms are written by Mathematics or Physicians which are based on their 
calculations. People in business units often don't understand the logic behind while 
Mathematics and Physicians are not aware of the proper variable and level of the 
investigated problem. Thus, there is a magic number code problem. To bring the humans 
and the ML-algorithm on the same stage and foster its understanding in order to understand 
the ML/AI- decision making will be a huge challenge and requires new employees 
capabilities and skills.  
• Data transparency and storage problems are new challenges the companies have to face. 
ISO norms have to be complied with. Regulations regarding data protections laws and 
conformity with existing regulations need to be proofed. 
4. In your point of view, what are the main capabilities of ML and which technologies and 
functions may be enabled by these capabilities in the future? 
Basically, ML- automatization functions and capabilities can be everywhere implemented 
within the company where the human is not better than the system. Thus, it can enhance typical 
“human-jobs”. Moreover, it can be implemented where huge data points exist and everywhere 
where the company can find repetitive tasks.  
The biggest potentials are:  
- Automatization where changes are made often (laws)  
- Pattern recognition and classification of data into groups  (image/ voice recognition)  
5. In which business units (R&D/ marketing/sales/supply chain etc.) of a (pharmaceutical) 
company would you see highest potentials for ML applications in the future? 
First of all most of the processes within every business unit can be improved by ML- algorithms 
in order to save time, costs, working more efficient and productive. Especially, within the R&D 
department are big potentials e.g. material machining, material processing. 
Within the production a lot of processes like component tracking, incoming and outgoing goods 
etc. have a high RPA potential. Employees also could be trained and supported by visual 
mimicking.  
Dynamic planning e.g. sales forecasting, spare part forecasting, machine maintenance and error 
analysis. 
All of this affects the revenue and profits of the companies.  
6. What do you think are the main challenges for implementing ML algorithms in a 




The real challenge is to use the existing algorithms and convert and edit them to your individual 
needs to accomplishing the required output. Another big challenge will be the risk management 
and regulation compliance because the companies often deal with sensitive data and 
information which have to be protected.  
7. Where do you identify the biggest potentials for ML in the sales process and what do 
you think which tasks could be supported in the future sales process through ML? 
He does not know exactly the sales process but you can implement ML-applications and 
functions where data exist. Forecasting, dynamic planning and customer interaction can be 
fields where ML applications might play a significant role.  
8. Do you think that a full automatized sales process is realistic and could fully replace 
humans? 
Yes, could be. The important thing to understand is why the customer buys a product or a 
service. In that sense it is important to build a profile around the customer which recognized 
the customer’s preferences, habits and purchasing triggers. However currently we need the 
human in order to teach the system/ the algorithm because the algorithm by itself doesn't know 
the solution for a customer requirement yet.  
9. Where do you see machine learning in 5 years/ 10 years? 
This is hard to say and I really don't know but I think it is an exponential technology which 
hasn't reached its full potential yet. Their will be more and more use cases and new business 
models around this technology in combination with data management systems. There will be a 
lot more ML/AI solutions as services in future, meaning to sell AI/ML solutions as new 
products.   
Summary Interviewee 4 
Interviewee 4 has a background in computer science. He worked in several startups as a 
software developer and also consulted business in terms of software strategies. He is now the 
head of Porsche digital, the new mobility and service hub of Porsche in Ludwigsburg, Stuttgart. 
He assumes that ML and its applications haven’t reached its full potential yet and describes the 
current phase as the ML implementation phase. He highlights that it is possible to scale up ML 
applications but that this requests a very new way of thinking about ML algorithms. He also 
mentioned China as a very credible source of ML literature. Moreover he identifies three main 
challenges for the ML integration within companies, namely ML algorithm adaption, ML 
algorithm understanding and data transparency and storage. Regarding the adaption of 
algorithms the biggest challenge is to implement the modified algorithms within the company 
meaning within the existing systems, which also have to be aligned and adapted. Most of the 
algorithms are written by Mathematics or Physicians which are based on their calculations. 
People in business units often don't understand the logic behind while Mathematics and 
Physicians are not aware of the proper variable and level of the investigated problem. Thus, 
there is a magic number code problem which can be overcome through educational work. Data 
transparency and storage problems are new challenges the companies have to face. ISO norms 
have to be complied with. Regulations regarding data protections laws and conformity with 
existing regulations need to be proofed. In his opinion ML algorithms can be implemented 
everywhere where the human is not better than the machine. Thus, it can enhance typical 
“human-jobs”. Moreover, it can be implemented where huge data points exist and everywhere 
where the company can find repetitive tasks. However, the biggest potentials has 
automatization where changes are made often (laws) and pattern recognition and classification 
of data into groups through NLP. He seems ML as an additional source of revenue. Especially, 
within the R&D department are big potentials e.g. material machining, material processing. 
Within the production a lot of processes like component tracking, incoming and outgoing goods 
etc. have a high RPA potential. Employees also could be trained and supported by visual 
mimicking. Dynamic planning e.g. sales forecasting, spare part forecasting, machine 
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maintenance and error analysis. Regarding the sales process, which he is not aware of sees ML-
applications and functions everywhere where data exist. Forecasting, dynamic planning and 
customer interaction can be fields where ML applications might play a significant role. 
Especially the ability of ML algorithms to understand why the customer buys a product or a 
service can be essential. In that sense it is important to build a profile around the customer 
which recognized the customer’s preferences, habits and purchasing triggers. In the future he 
underlines the fact that there will be more and more use cases and new business models around 
this technology in combination with data management systems. 
The Impact of Machine Learning on the efficiency of the B2B Sales Service in 
Pharmaceutical Companies 
 
RQ: How can Machine Learning-enabled tech/functions maximize the efficiency of the B2B 
Sales Service for Pharmaceutical Companies in future? 
 
Interviewer: Mr. Tobias Brengel       Date: 01.06.2019 
Interviewee: Interview 5 
 
1. Please introduce yourself briefly and describe your position within your company/ 
university/ field of research. 
Interviewee 5 is an employee of KPMG working in the field of CIO advisory. He is experienced 
in the field of data science and mainly has a technological background. During his studies he 
focused on Physics while currently he is undertaking data scientist work.  
2. Do you think the rise and importance of AI/ ML will continue to grow or do you think 
the technological limitation has risen? Why do you think so? 
First of all he highlights “The morning papers” as additional sources for gathering insights in 
the topic of AI/ML. Moreover, he confirms that not limits are exist for ML enabled technologies 
and functions. AI consists of a variety of different algorithms and ML should have the ability 
to self-adapt to the required data and to the demanded outcome. In the development of the 
technology there were first clusters then cloud solutions and functional services. Also the ML 
algorithms but also the hardware were they perform in developing constantly. Some algorithm 
underline only specific tasks and have to developed based on the required outcomes which 
requires a reasonable knowledge about it.  
3. What do you think are the key challenges for the future development of ML? 
• First of all the establishment of new IT-Infrastructure is required to generate new value. 
Sometimes this goes along with system changes. Moreover, this changes the entire 
business model because the IT department is becoming the core of the digital business 
models especially in pharma’s. This is due to the fact that the IT department is the highly 
profitable and not only a department which requires high investments.  
• The IT-department requires freedom in their way to undertake tasks and thus needs 
enabler of efficient ML strategy’s and a positive integration within the business model. 
The majority of the enterprises does not have created that basis yet. The flawless access to 
data, less homogeneity in the data and a bigger ERP systems go along with a successful 
implementation.  
• The next challenges lays in the IT-department because they do not communicate their 
results and request well. However, also the top-management has the duty to interact with 
the IT-department to overcome misunderstandings. Therefore the management has to 
ensure that employees getting educated according to ML/ algorithms developments and its 
usage. Trust can be generated to small things which facilitate the workers workflow, e.g. 
the integration of buttons which overtake a simple task.  
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4. In your point of view, what are the main capabilities of ML and which technologies 
and functions may be enabled by these capabilities in the future? 
There are three major applications/ technologies based on ML:  
• RPA is a common hot topic within the consulting sector fostering efficiency within 
operations, saving costs as well decrease errors within the process.  
• Text and picture recognition is highlighted as well for example for contract management. 
The identification of pictures can be valuable within the production unit where process can 
be tracked easily and serial numbers are identified without problems 
• Forecasting and Predictions are also important technologies within the process and 
operations management. While determine potential error sources.  
5. In which business units (R&D/ marketing/sales/supply chain etc.) of a 
(pharmaceutical) company would you see highest potentials for ML applications in the 
future? 
Within pharma’s you can implement ML algorithms everywhere, throughout the entire value 
chain.  The overall goal is to increase the performance. Doing so within the production costs 
(e.g. for planning) can be significantly reduced, within the sales departments margins can be 
increased by the establishment of longer credible customer relationships, in the purchasing 
department can be through a good planning costs savings. Also the facility management can be 
supported by robots who overtake supportive tasks e.g. cleaning or maintenance tasks.  
6. What do you think are the main challenges for implementing ML algorithms in a 
company not using ML so far? What are the success factors of implementing efficient 
ML routines? 
A challenge for companies is to implement ML solutions in a small costs reaching fast reactions 
and outcomes. The general integration is expensive and takes a data scientist 20 to 400 days in 
order to deal with missing data, errors establishing a proficient deep learning system. In 
company which already fostered innovation and technologies that can be reduced due to the 
different set up and prerequisites. However, nowadays a valuable price model requires at least 
10-50 evidences which is not too much. When the IT-structure is not established yet, companies 
can buy data easily.  
7. Where do you identify the biggest potentials for ML in the sales process and what do 
you think which tasks could be supported in the future sales process through ML? 
The biggest potentials are within the offering phase. A well supported pricing is in a heavily 
related pharma environment a good trigger to foster sales and profits. Moreover, ML algorithm 
can support the offering for the customer by identifying its needs, but also taking into the 
account environmental factors as well as examples and outliers.  
8. Do you think that a full automatized sales process is realistic and could fully replace 
humans? 
Yes it can happen, but for the moment machines need humans to instruct them 
9. Where do you see machine learning in 5 years/ 10 years? 
More and more touchpoint will be established in the future years but a real evaluation is 
impossible at the current stage. The trend is based on general AI and automatizations which 
foster productivity and efficiency within the society.  
Summary Interviewee 5 
Interviewee 5 is an employee of KPMG working as a data scientist in the field of CIO advisory. 
He deals with the implementation of RPA solutions within HR, logistics, procurement and 
production. He is experienced in the field of data science and mainly has a technological 
background. During his studies he focused on Physics while he was interesting about new 
technologies. He agrees that the rise of ML technologies and applications only has started yet. 
In order to put ML to the next level it is necessary to enable the algorithm to adapt itself to new 
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environments, new outcomes etc.  He mentioned the 3 biggest challenges, namely: IT-
infrastructure, Freedom for IT-departments and Communication:  
The implementation of ML algorithms often goes along with system changes. Moreover, this 
changes the entire business model because the IT department is becoming the core of the digital 
business models especially in pharma’s. Thus, the right set up is essential. He also highlights 
that the IT-department requires freedom and support meaning the flawless access to data, less 
homogeneity in the data and a bigger ERP systems. Thirdly, communication through the entire 
business/ company has to be ensured because otherwise the technology is used in a wrong way 
or misunderstandings come up. Trust can be generated slowly to small things which facilitate 
the workers workflow, e.g. the integration of buttons which overtake a simple task. Concerning 
the main capabilities of ML he mentioned RPA, NLP as well as Predictions. He names RPA as 
a common hot topic within the consulting sector fostering efficiency within operations, saving 
costs as well decrease errors within the process. According to NLP he states example for 
contract management examples supported by text recognitions. In the production he identifies 
picture recognition potential which meaning processes can be tracked easily and serial numbers 
are identified without problems 
Forecasting and Predictions are also important technologies within the process and operations 
management. The have the potential to determine error sources. Within pharma’s ML can help 
to improve the performance in every unit. Doing so the production costs (e.g. for planning) can 
be significantly reduced, within the sales departments margins can be increased by the 
establishment of longer credible customer relationships, in the purchasing department also 
appear costs savings through credible planning. He concludes that in the future years more and 
more ML-touchpoint will be established in the entire business value chain but a real evaluation 
is impossible at the current stage. 
The Impact of Machine Learning on the efficiency of the B2B Sales Service in 
Pharmaceutical Companies 
 
RQ: How can Machine Learning-enabled tech/functions maximize the efficiency of the B2B 
Sales Service for Pharmaceutical Companies in future? 
 
Interviewer: Mr. Tobias Brengel       Date: 23.06.2019 
Interviewee: Interview 5 
 
1. Please introduce yourself briefly and describe your position within your company 
Justus is working at Syte, a consultancy boutique specialized in digital health strategy mainly 
supporting their clients towards tailored client digital health solutions and building up new 
digital healthcare services and core products. Moreover, academic contributions on new 
technological trends in the area of e.g. AI/ Ml in the Digital Health landscape are published by 
Syte.  
2. What’s your company’s position in the pharmaceutical industry and how would you 
describe your company in terms of type; dimension and market? 
Type: Small consultancy boutique specialized in medtech, pharma and insurance with big 
clients like Allianz or MetLife 
Dimension: 30 employees  
Markets: healthcare-, pharma- and insurance-industry 
3. What are the biggest challenges for your company at the moment? 
Most of the pharmaceutical companies lacking in terms of digitization and technology. For 
them the digital world is quite new because PC’s background is rather “drug” and R&D 
development rather than using a digital approach in order to implement e.g. new technological 
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solutions within their business units. To integrate technological solution, changing business 
models and become data-driven are big challenges for PC’s at the moment.  
4. What are the most important key performance indicators (KPI’s) within your sales 
department?  
Often, sales forces have revenue targets and specific sales goals. However, these targets often 
depend on the market: (OTC vs. GKV vs. PKV – in Germany) 
Another component is the knowledge of the salesforces, because often sales representatives 
have to be experts in the field where they sell in order to serve the client best.  
5. Which different sales types exist within your company and who are they targeting? 
That also depends on the particular PC. Some pharma companies lay their salesforce off 
because they are not required anymore. However similar to the KPI’s section it also depends 
on the market (OTC/GKV/PKV) 
6. Given your opinion what are the typical tasks in your B2B sales department? Are 
they classified (e.g. repetitive vs non-repetitive tasks/standardized vs. non-
standardized tasks/daily vs. weekly vs monthly tasks)? 
The typical task of sales representatives is to work scientific using an educational approach to 
guarantee an expert status in order to answer every question the client might ask. Moreover, 
sales representatives creating a marketing push in order to arouse interest in the new product. 
Often the target group are doctors who have no time. That is why, pitches/ product presentations 
need to be on point, tailored, short and precise. In that sense, the representatives have to be 
available for their customers 24/7, because in case there are important questions arising it is 
important to respond quickly to client’s request.  
7. What are the biggest challenges of the internal B2B sales process? 
Basically, the biggest challenge the sales representatives are facing is time. On the micro-level 
doctors don't have time to listen to the representative (only 5-10min max.). Therefore, the 
salesforce need to transfer the complex message quickly. Moreover, the salesforce needs to 
organize their schedule (time and location) effectively because to arrange meetings with doctors 
and other potential clients seems very difficult.  
On the macro-level it is important to cover all potential clients geographically and to analyze 
the lessons learned from previous sales.  
8. In your point of view, what are the main capabilities of ML and which technologies 
and functions may be enabled by these capabilities in the future? 
AI/ML are self-trained systems which have a greater ability to discover pattern easier (with less 
effort) than the humans. Often, it solves problems which cannot be solved by humans. Since it 
can compare a huge combination of variables ML can derive results the human cannot discover.  
9. In which business units of a (pharmaceutical) company would you see highest 
potentials for ML applications in the future?  
The biggest potential is probably in the R&D area. With ML clinical trials might be enhanced 
and thus, customer interaction might be improved too.  
10. What do you think are the main challenges for implementing ML algorithms in a 
company not using ML so far? What are the success factors of implementing efficient 
ML routines?  
The challenge of PC’s is nowadays to guarantee the data access. For organizations is essential 
to educate and train the employees in order to point out which potentials AI/ML may have and 
how to use it effectively. For that, PC have to reorganize their business units and position 
themselves new, including new service units.   
11. Do you think that a full automatized sales process is realistic and could fully replace 
humans?  
Also in future, not everything can be automatized, since the human component is essential. 
Fields of implementation might be:  
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In short term: process optimization/ support 
In middle term: Taking individual/ own decisions 
In long term: Self-control and optimization of processes and operations  
Summary interviewee 6 
Interviewee 6 is working in  a consultancy boutique specialized in digital health strategy mainly 
supporting their clients towards tailored client digital health solutions and building up new 
digital healthcare services and core products. Moreover, academic contributions on new 
technological trends in the area of e.g. AI/ Ml in the Digital Health landscape are published by 
his company. As a pharma experts he confirms that pharma’s lacking in terms of digitization 
and technology. For them the digital world is quite new because their background is rather 
“drug” and R&D development than using a digital approach in order to implement e.g. new 
technological solutions within their business units. To integrate technological solution, 
changing business models and become data-driven are big challenges for pharma’s at the 
moment. He mentions that the salesforce often have specific and challenging goals which 
depend on the market: (OTC vs. GKV vs. PKV – in Germany). Moreover, he describes them 
as a valuable source of knowledge. The common tasks of sales reps is customer service meaning 
that the salesforce uses an educational approach to guarantee an expert status in order to answer 
every question the client might ask. Sales representatives must create a marketing push in order 
to arouse interest in the new product. Often the target group are doctors who have no time. That 
is why, pitches/ product presentations need to be on point, tailored, short and precise. In that 
sense, the representatives have to be available for their customers 24/7, because in case there 
are important questions arising it is important to respond quickly to client’s request. . On the 
micro-level doctors don't have time to listen to the representative (only 5-10min max.). 
Therefore, the salesforce need to transfer the complex message quickly. On the macro-level it 
is important to cover all potential clients geographically and to analyze the lessons learned from 
previous sales. There he sees machine learnings greatest potential because these systems are 
self-trained and have a greater ability to discover pattern easier (with less effort) than the 
humans. Often, it solves problems which cannot be solved by humans. The main challenge he 
identifies for pharma’s is nowadays to guarantee the data access. For organizations is essential 
to educate and train the employees in order to point out which potentials AI/ML may have and 
how to use it effectively. For pharma’s it means to reorganize their business units and position 
themselves new, including new service units. The potential fields in sales are according to him 
process optimization/ support (short term), Taking individual/ own decisions (middle term), 
self-control/ optimization (long term). 
The Impact of Machine Learning on the efficiency of the B2B Sales Service in 
Pharmaceutical Companies 
 
RQ: How can Machine Learning-enabled tech/functions maximize the efficiency of the B2B 
Sales Service for Pharmaceutical Companies in future? 
 
 
Interviewer: Mr. Tobias Brengel       Date: 17.05.2019 
Interviewee: Interviewee 7 
 
1. Please introduce yourself briefly and describe your position within your company 
Interviewee is a current employee of Novartis. He is currently in the financial department within 
the commercial commission in “general pharma”. He is currently dealing with AI/ML in a cash 




2. What’s your company’s position in the pharmaceutical industry and how would you 
describe your company in terms of type; dimension (employees) and market (markets 
your company is targeting)? 
Company: Novartis 
Employees: 125.000 
Market: Biotech- & Pharmaceutical Company  
3. What are the biggest challenges for your company at the moment? 
The biggest challenge for Novartis is currently the restructuring due to the new CEO (2018). 
Since Novartis was specialized also in vet-medicine/ generic drug development etc. the new 
approach is to follow more cutting edge therapies. These therapies and particular drugs have 
high R&D costs and thus, are very expensive for the end-consumer. E.g. a one-time therapy to 
combat leukemia cost 500.000€ with refund policy in case the therapy doesn’t affect the patient. 
The challenge is that most of the patients cannot afford this expensive therapies and drugs, thus 
there is a huge pressure on health insurance companies. That is why the question is how 
companies can access new treatments to an affordable price for the end-consumer. Moreover, 
there are country specific restrictions e.g. for Marketing where in the US open “drug marketing” 
is possible, whereas in Germany/ CH it’s forbidden. 
4. What are the most important key performance indicators (KPI’s) within your sales 
department? 
It also depends on the country. In Germany it is forbidden to track the rev/salesforce/doctor 
because that will lead to bias results. In the Switzerland it is possible. However, sales 
representatives have clear defined goals they have to achieve. That is why client calls, closing 
ration or client meetings (how often) are tracked. Moreover, the particular sales representative 
needs to document the meetings outcome/ content and has to track how the conversation went 
and which problems the client might have. 
5. Which different sales types (inside/outside sale, client services, lead generation etc.) 
exist within your company and who are they targeting? 
Mostly exist sales representative which are mainly focused on the doctors because the doctors 
and hospitals are the decision makers and based on them the purchases are made.  
Typical B2B process is the following: 
 
In case the Novartis sell huge amounts to particular wholesales companies key accountants 
mange the sales/interaction and relationship. 
6. What are the typical steps of the B2B sales process within your company? 
Same steps. 
7. Given your opinion what are the typical tasks in your B2B sales department? Are they 
classified (e.g. repetitive vs non-repetitive tasks/standardized vs. non-standardized 
tasks/daily vs. weekly vs monthly tasks)? Are there any tasks outsourced? 
The sales tasks are usually not outsourced because it is important to establish a strong client-
representative relationship. Sales responsibilities can be first to interact with the doctors, later 
managing and control specific regions/areas. The responsibility will increase during time. 
Moreover, typical sales tasks are cold calling, client meetings, consulting, relationship 
management, identification new clients. 
 8. What are the biggest challenges of the internal B2B sales process? 
Customer Doctor/Hospital Drug Store Wholesale Pharmaceutical Company
 
 AA 
The biggest challenges are to fulfill the challenging preset goals. Sales representatives are under 
time pressure and always on track. They need to save time e.g. for traveling, checking mails 
and documentation of client meetings. 
9. In what level, technology is already integrated within the sales process in order to 
support the mentioned tasks and challenges? Are there technological incentives within 
your company to foster technology? 
Novartis has a tech-hub in Barcelona which deals with new technologies AI/ML and new Apps.  
ML is mostly used to predict actual forecasts with a high percentage of accuracy. An example 
is balance sheet prediction as well as the forecasts of specials sales events and its potential sales 
volume and of course yearly sales rates. Moreover, an app was released to support the 
documentation and travel planning process of sales representatives. Besides, an app for real 
time data about the company was released to give employees an overview about e.g. yearly 
sales, revenue and other company related information. 
10. What are the lessons learned from the implementation of a new technology? 
Data Scientists, physicians or math experts are lacking in terms of business know-how meaning 
that their chosen variables for sales forecasts might be completely different from the ones 
business people are choosing. There must be an exchange between the “IT-guys” and the 
business unit in order to use new technology and smoothen the integration process.  
11. Are there any AI/ ML applications already implemented in the current sales process? 
The app which he described up.  
12. What do you think at which touchpoints ML could support your daily work? 
Forecasting and prediction -> Optimization and time saving. 
Summary Interview 7 
Interviewee is a current employee of Novartis. He is currently in the financial department within 
the commercial commission in “general pharma”. He is currently dealing with AI/ML in a Cash 
flow project. He undertook a dual study program in Roche and undertook his master in Finance 
at ESADE.  
From his point of view the biggest challenge of pharma’s is the access to new treatments to an 
affordable price for the end-consumer.  
Moreover, there are country specific restrictions e.g. for Marketing where in the US open “drug 
marketing” is possible, whereas in Germany it’s forbidden. According to interviewee 7 sales 
representatives have clear defined goals they have to achieve, but they are constantly on track 
and under time pressure.  
That is why client calls, closing ration or client meetings (how often) are tracked. Moreover, 
the particular sales representative needs to manually document the meetings outcome/ content 
and has to track how the conversation went and which problems the client might have. Most of 
the clients are doctors, hospitals, drug stores and wholesales who are often restricted in time. 
Sales responsibilities start with interacting with the doctors, later managing and control specific 
regions/areas. The responsibility will increase during time. Moreover, typical sales tasks are 
cold calling, client meetings, consulting, relationship management, identification new clients.  
Besides, he agreed on the sevens steps of the sales tasks but mentioned that they don’t have a 
clear separation between particular steps and responsibility. According to him pharma’s started 
to shift their focus more on digital within the last years. In his department ML is mostly used 
to predict actual forecasts with a high percentage of accuracy. An example is balance sheet 
prediction as well as the forecasts of specials sales events and its potential sales volume and of 
course yearly sales rates. Moreover, an app was released to support the documentation and 
travel planning process of sales representatives. Besides, an app for real time data about the 
company was released to give employees an overview about e.g. yearly sales, revenue and other 
company related information.  
 
 BB 
The problem he sees is the communication between the department and the hub which develops 
Novartis specific algorithms in Spain in terms of that the choose variables of data scientists for 
sales forecasts might be completely different from the ones business people are choosing. He 
mentioned that there must be an exchange between the “IT-guys” and the business unit in order 
to use new technology and smoothen the integration process. 
The Impact of Machine Learning on the efficiency of the B2B Sales Service in 
Pharmaceutical Companies 
 
RQ: How can Machine Learning-enabled tech/functions maximize the efficiency of the B2B 
Sales Service for Pharmaceutical Companies in future? 
 
 
Interviewer: Mr. Tobias Brengel       Date: 31.06.2019 
Interviewee: Interviewee 8 
 
1. Please introduce yourself briefly and describe your position within your company 
Interviewee is currently employed as a pharmacist at a pharmacy in a small city with about 
11.000 inhabitants. He was able to gain 30 years of practical experience working as a 
pharmacist for various pharmacies. After studying at Johann-Wolfgang-Goethe University in 
Frankfurt he attained his state exam in pharmacy and his approbation to work as a pharmacist. 
2. What’s your company’s position in the pharmaceutical industry and how would you 
describe your company in terms of type; dimension (employees) and market (markets 
your company is targeting)? 
Company: Pharmacy 
Employees: 3 Fulltime-employees, 5 Part-time-employees, averaging about 6 FTE per workday  
Market: Direct distribution of pharmaceuticals and prescription drugs to the final customer 
3. What are the biggest challenges for your company at the moment? 
The growth of online pharmacy business in general is a huge challenge for conventional 
pharmacies. They are oftentimes able to offer pharmaceuticals at a significantly lower price due 
to advantages in cost of personnel and economies of scale. Conventional pharmacies have to 
build on advantages like better service and face-to-face medical advice. 
The introduction of digital prescriptions in Germany, promoted by minister of health Jens Spahn 
might pose a significant threat to brick-and-mortar pharmacies in the whole country. While 
doctors are currently only allowed to issue prescriptions for drugs and pharmaceuticals in a 
printed form, they might have the ability to issue them as a digital document. Patients then 
would be able to directly transfer those prescriptions to their chosen online pharmacy. The 
conventional pharmacies would get completely left out in this transaction or at least lose a 
significant amount of business and revenue. 
Rising complexity in legal restrictions and a rising number of “Pharmazentralnummern” in 
recent years have also lead to a steady increase in administrative effort. Therefore a lot of 
workforce is forced to do a lot of manual administrative tasks on a daily basis that cannot be 
automated due to regulations requiring them to be in filed in an analogue form. 
4. What are the most important key performance indicators (KPI’s) within your sales 
department? 
It also depends on the country. In Germany it is forbidden to track the rev/salesforce/doctor 
because that will lead to bias results. In the Switzerland it is possible. However, sales 
representatives have clear defined goals they have to achieve. That is why client calls, closing 
ration or client meetings (how often) are tracked. Moreover, the particular sales representative 
needs to document the meetings outcome/ content and has to track how the conversation went 
and which problems the client might have. 
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5. Which different sales types (inside/outside sale, client services, lead generation etc.) 
exist within your company and who are they targeting? 
The pharmacy mostly targets final customers of drugs and pharmaceuticals. Due to its character 
as a brick-and-mortar store the pharmacy is only limited to regional customers that mostly live 
in the city the pharmacy is located in or that live in smaller villages in the area without a 
pharmacy.  
There is also some form of B2B-sales as the pharmacy delivers medicine to a few local 
retirement homes. For an additional surcharge this service also includes a blistering service of 
medicine in individual packaging for individual patients. 
6. What are the typical steps of the B2B sales process within your company? 
There is no typical B2B-process in pharmacy. 
The steps from the perspective of a typical pharmaceutical wholesaler are: 
1) A sales representative directly contacts the pharmacy via mail or phone 
2) The sales representative visits the pharmacy for face-to-face negotiations 
3) During negotiations the sales representative can only offer a smile  
7. Given your opinion what are the typical tasks in your B2B sales department? Are they 
classified (e.g. repetitive vs non-repetitive tasks/standardized vs. non-standardized 
tasks/daily vs. weekly vs monthly tasks)? Are there any tasks outsourced? 
This question is not applicable for the sales process of a typical pharmacy. 
From the perspective of a pharmaceutical wholesaler:  
Sales employees are usually employed directly by the wholesaler 
 8. What are the biggest challenges of the internal B2B sales process? 
This question is not applicable for the sales process of a typical pharmacy. 
9. In what level, technology is already integrated within the sales process in order to 
support the mentioned tasks and challenges? Are there technological incentives within 
your company to foster technology? 
On every level of the sales process of pharmaceuticals a lot of documentation has to be filed. If 
these documentation processes could be more automated i.e. through technologies of Intelligent 
Automation the overall workload could be reduced significantly. This work effort could be 
invested in more important tasks like the advisory of patients and customers. A challenge in the 
implementation of such technologies is that the respective documentation usually has to be filed 
and stored in an analogue way on paper and in a written form. 
10. What are the lessons learned from the implementation of a new technology? 
Oftentimes the implementation of new technology can bring more complexity and more work 
effort for the employees in a pharmacy. Regulatory bodies usually believe that they are able to 
implement more laws and regulations due to overall technological progress. They imply that 
there is no rise in overall workload caused by more regulations because information technology 
can facilitate a decrease in necessary workload that evens out the additional workload of more 
regulations.  
11. Are there any AI/ ML applications already implemented in the current sales process? 
There are currently no AI/ML applications in the sales process of the pharmacy. 
12. What do you think at which touchpoints ML could support your daily work? 
These technologies have a lot of potential to automate manual, error-prone processes. An 
implementation as early in the sales process as at the doctor’s office that issues the prescription 
could already reduce a lot of work effort along the complete process. 
These technologies can also be used to provide more individualized customer service in the 
sales process. On the basis of customer or medical data up-selling and customer care potential 
could be identified for the benefit of both parties. 
A lot of customers seek medical advice from their pharmacists. This advice could become more 
useful and personalized if a ML/AI application could help identify the customer needs based 
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on previously collected data and the described symptoms. The pharmacists could issue the best 
fitting drug and could also avoid the risk of issuing a substance that the customer is allergic to. 
Summary Interview 8 
Interviewee 8 gained 30 years of practical experience working as a pharmacist for various 
pharmacies. After studying at Johann-Wolfgang-Goethe University in Frankfurt he attained his 
state exam in pharmacy and his approbation to work as a pharmacist. The biggest challenges 
he identified in the growth of online pharmacy business. They are oftentimes able to offer 
pharmaceuticals at a significantly lower price due to advantages in cost of personnel and 
economies of scale. Conventional pharmacies have to build on advantages like better service 
and face-to-face medical advisory, same as sales reps from big pharma companies. The second 
challenge is rising complexity in legal restrictions and a rising number of 
“Pharmazentralnummern” in recent years have also lead to a steady increase in administrative 
effort. Therefore a lot of workforce is forced to do a lot of manual administrative tasks on a 
daily basis that cannot be automated due to regulations requiring them to be in filed in an 
analogue form which is time consuming and monotonous. Within pharmacies is no typical 
B2B-process implemented but interviewee 8 identified the steps from the perspective of a 
typical pharmaceutical wholesaler as: 
1) A sales representative directly contacts the pharmacy via mail or phone 
2) The sales representative visits the pharmacy for face-to-face negotiations 
3) During negotiations the sales representative can only offer a smile  
On every level of the sales process of pharmaceuticals a lot of documentation has to be filed. If 
these documentation processes could be more automated i.e. through technologies of Intelligent 
Automation the overall workload could be reduced significantly. This work effort could be 
invested in more important tasks like the advisory of patients and customers. These technologies 
have a lot of potential to automate manual, error-prone processes. An implementation as early 
in the sales process as at the doctor’s office that issues the prescription could already reduce a 
lot of work effort along the complete process. 
These technologies can also be used to provide more individualized customer service in the 
sales process. On the basis of customer or medical data up-selling and customer care potential 
could be identified for the benefit of both parties. 
A lot of customers seek medical advice from their pharmacists. This advice could become more 
useful and personalized if a ML/AI application could help identify the customer needs based 
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